

---

**REFERENCE**

Koves,E.M. Use of high-performance liquid chromatography-diode array detection in forensic toxicology, *J.Chromatogr.A*, **1995**, 692, 103–119.

---

**SAMPLE**

**Matrix:** solutions

---

**HPLC VARIABLES**

**Column:** 250 × 4.6 10 μm Chiralcel OJ

**Mobile phase:** MeOH

**Flow rate:** 0.5

**Injection volume:** 20

**Detector:** UV 210

---

**CHROMATOGRAM**

**Retention time:** 10 (R-(+)), 16 (S-(-))

---

**OTHER SUBSTANCES**

**Simultaneous:** metabolites, 5-hydroxyglutethimide

---

**KEY WORDS**

chiral

---

**REFERENCE**

Weinz,C.; Blaschke,G.; Schiebel,H.-M. Investigation of the stereoselective in vitro biotransformation of glutethimide by high-performance liquid chromatography and capillary electrophoresis, *J.Chromatogr.B*, **1997**, 690, 233–242.

---

---

# Glyburide


**Molecular formula:** C<sub>23</sub>H<sub>28</sub>ClN<sub>3</sub>O<sub>5</sub>S

**Molecular weight:** 494.01

**CAS Registry No.:** 10238-21-8

**Merck Index:** 4486

**Lednicer No.:** 2 139



---

**SAMPLE**

**Matrix:** blood

**Sample preparation:** 2 mL Whole blood or plasma + 2 mL buffer + 5 mL chloroform:isopropanol:n-heptane 60:14:26, shake gently horizontally for 10 min, centrifuge at 2800 g for 10 min. Remove the lower organic layer and evaporate it to dryness under vacuum at 45°, reconstitute the residue in 100 μL mobile phase, centrifuge at 2800 g for 5 min, inject a 50 μL aliquot of the supernatant. (Buffer was saturated ammonium chloride solution 25% diluted with water, adjusted to pH 9.5 with 25% ammonia solution.)

---

**HPLC VARIABLES**

**Column:** 300 × 3.9 4 μm NovaPack C18

**Mobile phase:** MeOH:THF:buffer 65:5:30 (Buffer was 0.68 g/L (10 mM (sic)) KH<sub>2</sub>PO<sub>4</sub> adjusted to pH 2.6 with concentrated orthophosphoric acid.) (At the end of each session wash the column with water for 1 h and MeOH for 1 h, re-equilibrate for 30 min.)

**Column temperature:** 30

**Flow rate:** 0.8

**Injection volume:** 50

**Detector:** UV 229

**CHROMATOGRAM****Retention time:** 6.25**Limit of detection:** <120 ng/mL**KEY WORDS**

whole blood; plasma; interferences may occur—compounds (all of which are extracted) elute in this order: tenoxicam; iproniazid; methocarbamol; methotrexate; caffeine; nialamide; colchicine; cytarabine; benzoylecgonine; acetaminophen; diazoxide; dacarbazine; sulfinpyrazole; flumazenil; sulpride; morphine; atenolol; toloxatone; terbutaline; albuterol; phenobarbital; ranitidine; tiapride; phenol; chlormezanone; aspirin; metformin; ritodrine; codeine; sultopride; amisulpride; naltrexone; lisinopril; benzocaine; nizatidine; nalorphine; mephenesin; naloxone; sotalol; carteolol; procainamide; carbamazepine; bromazepam; nalbuphine; nadolol; procarbazine; dihydralazine; omeprazole; strychnine; acebutolol; glutethimide; chlorpropamide; glipizide; triazolam; prazosin; flunitrazepam; clonazepam; metoclopramide; melphalan; estazolam; tolbutamide; ephedrine; clonidine; pindolol; clobazam; minoxidil; disopyramide; nitrazepam; dextromethorphan; tofisopam; zopiclone; debrisoquine; sulindac; alprazolam; cycloguanil; lorazepam; methaqualone; ketamine; piroxicam; metoprolol; nifedipine; quinine; mephentermine; prilocaine; pentazocine; oxazepam; tiaprofenic acid; quinidine; celiprolol; ajmaline; yohimbine; lidocaine; secobarbital; viloxazine; mepruvacaine; meperidine; doxylamine; labetalol; temazepam; amodiaquine; benperidol; droperidol; hydroxychloroquine; zolpidem; ketoprofen; alminoprofen; cicletanine; moclobemide; chloroquine; cocaine; timolol; nomifensine; ticlopidine; acenocoumarol; vandesine; mexiletine; dipyridamole; trazodone; pipamperone; pyrimethamine; benazepril; vincristine; metapramine; chlordiazepoxide; oxprenolol; warfarin; clorazepate; flecainide; phenacyclidine; thiopental; fenfluramine; metipranolol; triprolidine; naproxen; buprenorphine; verapamil; buspirone; tianeptine; midazolam; bupivacaine; carbinoxamine; loprazolam; cetirizine; chlorpheniramine; moperone; cibenzoline; medifoxamine; astemizole; vinblastine; nicardipine; bisoprolol; diltiazem; glibenuride; reserpine; aconitine; nitrendipine; diazepam; mianserin; ramipril; haloperidol; tetracaine; alprenolol; aceprometazine; glibenclamide; chlorphenacinone; doxepin; nimodipine; diphenhydramine; cyclizine; histapyrodine; phenylbutazone; demexiptiline; clozapine; proguanil; trifluoperidol; medazepam; cyamemazine; bumadizone; suriclone; propranolol; acepromazine; dothiepin; dextromoramide; fenoprofen; dextropropoxyphene; loxapine; betaxolol; propafenone; promethazine; thioproperazine; methadone; amoxapine; quinupramine; opi Pramol; cyproheptadine; brompheniramine; mefenidramine; protriptyline; flurbiprofen; tetrazepam; zorubicin; prazepam; alimemazine; loperamide; imipramine; desipramine; levomepromazine; hydroxyzine; niflumic acid; penbutolol; fluvoxamine; pimozide; daunorubicin; indomethacin; maprotiline; tropatenine; etodolac; fluoxetine; amitriptyline; nortriptyline; tiocloamarol; diclofenac; mefloquine; trimipramine; chlorambucil; lidoflazine; ibuprofen; floctafenine; alpidem; loratadine; chlorpromazine; clomipramine; carpi-pramine; thioridazine; fentiazac; clemastine; mefenamic acid; fluphenazine; prochlorperazine; penfluridol; bepridil; terfenadine; trifluoperazine

**REFERENCE**

Tracqui, A.; Kintz, P.; Mangin, P. Systematic toxicological analysis using HPLC/DAD, *J. Forensic Sci.*, **1995**, *40*, 254–262.

**SAMPLE****Matrix:** blood, urine

**Sample preparation:** Add 1 mL whole blood or urine to Toxi-Tube A (Toxi-Lab, Irvine CA), add 3 mL water, mix by gentle inversion for 5 min, centrifuge at 1500 g for 5 min. Remove the organic layer and evaporate it to dryness under a stream of nitrogen at 40°, reconstitute the residue with 50 µL MeCN:water 50:50, vortex for 10 s, centrifuge at 7500 g for 2 min, inject a 10 (urine) or 30 (blood) µL aliquot. (The detector wavelength shown is the wavelength of maximum absorbance. This will not necessarily be the optimal wavelength for the separation. Multiple wavelengths from 200–350 nm can be scanned using a diode-array detector. Otherwise, 220 nm may be a reasonable choice for initial work. Matrix may interfere.)

**HPLC VARIABLES****Guard column:** 20 mm long Symmetry C18**Column:** 250 × 4.6 5 µm Symmetry C8 (Waters)

**Mobile phase:** Gradient. A was 50 mM pH 3.8 sodium phosphate buffer. B was MeCN. A:B 85:15 for 6.5 min, 65:35 for 18.5 min, 20:80 for 3 min (step gradient), re-equilibrate at initial conditions for 7 min.

**Column temperature:** 30

**Flow rate:** 1 for 6.5 min, to 1.5 over 18.5 min, maintain at 1.5 for 3 min (re-equilibrate at 1.5 mL/min)

**Injection volume:** 10-30

**Detector:** UV 200.5

## CHROMATOGRAM

**Retention time:** 21.953

## KEY WORDS

whole blood

## REFERENCE

Gaillard,Y.; Pépin,G. Use of high-performance liquid chromatography with photodiode-array UV detection for the creation of a 600-compound library. Application to forensic toxicology, *J.Chromatogr.A*, **1997**, 763, 149-163.

## SAMPLE

**Matrix:** solutions

## HPLC VARIABLES

**Column:** 250 × 4.6 Zorbax RX

**Mobile phase:** Gradient. A was 10 mL concentrated orthophosphoric acid and 7 mL triethylamine in 1 L water. B was 10 mL concentrated orthophosphoric acid and 7 mL triethylamine in 200 mL water, make up to 1 L with MeCN. A:B from 100:0 to 0:100 over 30 min, maintain at 0:100 for 5 min.

**Column temperature:** 30

**Flow rate:** 2

**Detector:** UV 210

## OTHER SUBSTANCES

**Also analyzed:** acepromazine, acetaminophen, acetophenazine, albuterol, aminophylline, amitriptyline, amobarbital, amoxapine, amphetamine, amyllocaine, antipyrine, aprobarbital, aspirin, atenolol, atropine, avermectin, barbital, benzocaine, benzoic acid, benzotropine, benzphetamine, berberine, bibucaine, bromazepam, brompheniramine, buprenorphine, buspirone, butabarbital, butacaine, butethal, caffeine, carbamazepine, carbromal, chloramphenicol, chlor-diazepoxide, chloroquine, chlorothiazide, chloroxylenol, chlorphenesin, chlorpheniramine, chlorpromazine, chlorpropamide, chlortetracycline, cimetidine, cinchonidine, cinchonine, clonbuterol, clonazepam, clonixin, clorazepate, cocaine, codeine, colchicine, cortisone, coumarin, cyclazocine, cyclobenzaprine, cyclothiazide, cyheptamide, cymarin, danazol, danthron, dapsone, debrisoquine, desipramine, dexamethasone, dextromethorphan, dextropropoxyphene, diamorphine, diazepam, diazepam, diclofenac, diethylpropion, diethylstilbestrol, diflunisal, digitoxin, digoxin, diltiazem, diphenhydramine, diphenoxylate, diprenorphine, dipyrone, disulfiram, dopamine, doxapram, doxepin, dronabinol, ephedrine, epinephrine, epinine, estradiol, estriol, estrone, ethacrynic acid, ethosuximide, etonitazene, etorphine, eugenol, famotidine, fenbendazole, fencamfamine, fenopropfen, fenproporex, fentanyl, flubendazole, flufenamic acid, flunitrazepam, 5-fluorouracil, fluoxymesterone, fluphenazine, furosemide, gentisic acid, gitoxigenin, glipizide, glunixin, guaiaicol, halazepam, haloperidol, hydrochlorothiazide, hydrocodone, hydrocortisone, hydromorphone, hydroxyquinoline, ibogaine, ibuprofen, iminostilbene, imipramine, indomethacin, isocarboxtyril, isocarboxazid, isoniazid, isoproterenol, isoxsuprine, ivermectin, ketamine, ketoprofen, kynurenic acid, levorphanol, lidocaine, lorazepam, lormetazepam, loxapine, mazin-dol, mebendazole, meclizine, meclofenamic acid, medazepam, mefenamic acid, megestrol, mepacrine, meperidine, mephentermine, mephentoin, mephesin, mephobarbital, mepivacaine, mescaline, mesoridazine, methadone, methamphetamine, methapyrilene, methaqualone, methazolamide, methocarbamol, methoxamine, methsuximide, methyl salicylate, methyl dopa, methyl dopamine, methylphenidate, methylprednisolone, methyltestosterone, methyprylon, metoprolol, mibolerone, morphine, nadolol, nalorphine, naloxone, naltrexone, naphazoline, naproxen, nefopam, niacinamide, nicotine, niacin, nifedipine, niflumic acid, nitrazepam, nor-epinephrine, nortriptyline, noscapine, nyldrin, oxazepam, oxycodone, oxymorphone, oxyphen-butazone, oxytetracycline, papaverine, pargyline, pemoline, pentazocine, pentobarbital, persantane, phenacetin, phenazocine, phenazopyridine, phencyclidine, phendimetrazine, phenelzine, pheniramine, phenobarbital, phenothiazine, phensuximide, phentermine, phenyl-butazone, phenylephrine, phenylpropanolamine, piperocaine, prazepam, prednisolone, primidone, probenecid, progesterone, propiomazine, propranolol, propylparaben, pseudoephedrine,

puromycin, pyrilamine, pyridylidone, quazepam, quinaldic acid, quinidine, quinine, ranitidine, recinnamine, reserpine, resorcinol, saccharin, albuterol, salicylamide, salicylic acid, scopolamine, scopoletin, secobarbital, strychnine, sulfacetamide, sulfadiazine, sulfadimethoxine, sulfaethidole, sulfamerazine, sulfamethazine, sulfamethoxazole, sulfanilamide, sulfapyridine, sulfasoxazole, sulindac, tamoxifen, temazepam, testosterone, tetracaine, tetracycline, tetramisole, thebaine, theobromine, theophylline, thiabendazole, thiamine, thiamylal, thiobarbituric acid, thioridazine, thiosalicylic acid, thiothixene, thymol, tolazamide, tolazoline, tobutamide, tolmetin, tranlycypromine, triamcinolone, tribenzylamine, trichloromethiazide, trifluoperazine, trihexyphenidyl, trimethoprim, tripeleminamine, triprolidine, tropacocaine, tyramine, verapamil, vincamine, warfarin, yohimbine, zoxazolamine


---

**REFERENCE**

Hill,D.W.; Kind,A.J. Reversed-phase solvent gradient HPLC retention indexes of drugs, *J.Anal.Toxicol.*, **1994**, *18*, 233–242.

---

# Glycerin



**Molecular formula:** C<sub>3</sub>H<sub>8</sub>O<sub>3</sub>

**Molecular weight:** 92.09

**CAS Registry No.:** 56-81-5

**Merck Index:** 4493

---

**SAMPLE**

**Matrix:** bulk

**Sample preparation:** Prepare an aqueous solution, inject an aliquot.

---

**HPLC VARIABLES**

**Guard column:** 10 μm Guard-pak (Waters)

**Column:** 250 × 4.6 5 μm Ultrasphere ODS C18

**Mobile phase:** MeCN:water 5:95

**Flow rate:** 1

**Detector:** RI

---

**REFERENCE**

Cannon,J.M.; Brown,R.D.; Murrill,E.M.; Jameson,C.W. Identification of components in iodinated glycerol, *J.Pharm.Sci.*, **1989**, *78*, 48–51.

---

**SAMPLE**

**Matrix:** bulk

**Sample preparation:** Prepare an aqueous solution, inject an aliquot.

---

**HPLC VARIABLES**

**Guard column:** 10 μm Guard-pak (Waters)

**Column:** 250 × 4.6 5 μm Ultrasphere ODS C18

**Mobile phase:** MeCN:water 5:95

**Flow rate:** 1

**Detector:** RI

---

**REFERENCE**

Viñas,P.; López Erroz,C.; Hernández Canals,A.; Hernández Córdoba,M. Liquid chromatographic analysis of sulfonamides in foods, *Chromatographia*, **1995**, *40*, 382–386.

---

**SAMPLE**

**Matrix:** formulations

**Sample preparation:** Remove the water from 10 μL syrup under reduced pressure for 10 min, reconstitute with 2 mL pyridine. Remove a 25 μL aliquot and add it to 75 μL reagent, shake well, let stand at room temperature for 10 min, evaporate to dryness under reduced pressure

at room temperature, flush the tube with a stream of air or nitrogen, add 2 mL 5% sodium carbonate solution containing 2.5 mg/mL 4-dimethylaminopyridine, shake or sonicate for 5 min, extract with 2 mL chloroform. Wash the extract with 2 mL 5% sodium bicarbonate solution, wash twice with 3 mL portions of 50 mM HCl containing 5% NaCl, inject an aliquot. (Prepare reagent by dissolving 100 mg 4-nitrobenzoyl chloride in pyridine with gentle warming.)

---

**HPLC VARIABLES**

**Column:** 150 × 3.5 µm LiChrosorb SI 60

**Mobile phase:** n-Hexane:chloroform:MeCN 10:3:1.9 containing 0.1% water

**Flow rate:** 1.4

**Injection volume:** 50

**Detector:** UV 260

---

**CHROMATOGRAM**

**Retention time:** 2.5

---

**OTHER SUBSTANCES**

**Simultaneous:** dextrose, fructose, propylene glycol, saccharose, sorbitol

---

**KEY WORDS**

syrup; derivatization; normal phase

---

**REFERENCE**

Nachtmann, F.; Budna, K.W. Sensitive determination of derivatized carbohydrates by high-performance liquid chromatography, *J. Chromatogr.*, **1977**, *136*, 279–287.

---

---

**SAMPLE**

**Matrix:** formulations

**Sample preparation:** Condition a C18 Sep-Pak SPE cartridge with 2 mL MeOH and 20 mL water. Dilute formulation ten-fold with water, add a 0.5 mL aliquot to the SPE cartridge, elute with three 1 mL portions of water, inject a 10 µL aliquot of the eluate.

---

**HPLC VARIABLES**

**Column:** 8 mm i.d. C18 radial compression (Waters)

**Mobile phase:** Water

**Flow rate:** 1

**Injection volume:** 10

**Detector:** RI

---

**CHROMATOGRAM**

**Retention time:** 3.4

---

**OTHER SUBSTANCES**

**Simultaneous:** dihydroxyacetone, dioxane, ethylene glycol, formic acid, glyceraldehyde, methylglyoxal, propylene glycol

---

**KEY WORDS**

SPE

---

**REFERENCE**

Bobin, M.F.; Martini, M.C.; Gudefin, A.; Cotte, J. Dosage de la dihydroxyacétone dans les émulsions [Assay of dihydroxyacetone in emulsions], *Farmaco. [Prat.]*, **1983**, *38*, 403–414.

---

---

**SAMPLE**

**Matrix:** formulations

**Sample preparation:** Weigh out 1–2 mL, add 20 mL water, mix thoroughly, make up to 100 mL with water, mix thoroughly, inject a 25 µL aliquot.

---

**HPLC VARIABLES**

**Guard column:** Micro-Guard ion exclusion cartridge (Bio-Rad)

**Column:** 300 × 7.8 Aminex HPX-87H (Bio-Rad)  
**Mobile phase:** 6.5 mM sulfuric acid  
**Column temperature:** 65  
**Flow rate:** 0.8  
**Injection volume:** 25  
**Detector:** RI

---

#### CHROMATOGRAM

**Retention time:** 11.62

---

#### REFERENCE

Del Grosso, A.V.; May, J.C. Gas chromatographic, liquid chromatographic, and titrimetric procedures for determination of glycerin in allergenic extracts and diagnostic antigens: comparative study, *J. Assoc. Off. Anal. Chem.*, **1987**, 70, 825–828.

---

#### SAMPLE

**Matrix:** solutions

**Sample preparation:** Inject a 10 µL aliquot of an aqueous solution.

---

#### HPLC VARIABLES

**Column:** 250 × 4.6 5 µm Supelcosil LC-NH<sub>2</sub>

**Mobile phase:** MeCN:water 75:25

**Column temperature:** 22

**Flow rate:** 1

**Injection volume:** 10

**Detector:** RI

---

#### CHROMATOGRAM

**Retention time:** 5

---

#### OTHER SUBSTANCES

**Simultaneous:** dextrose, fructose, maltose, sucrose

---

#### REFERENCE

Johnson, J.M.; Harris, C.H. Selecting the most effective filtration media for HPLC analysis of saccharides, *J. Chromatogr. Sci.*, **1987**, 25, 267–269.

---

#### SAMPLE

**Matrix:** solutions

---

#### HPLC VARIABLES

**Column:** ION-300

**Mobile phase:** 2.5 mM sulfuric acid

**Column temperature:** 70

**Flow rate:** 0.4

**Detector:** RI

---

#### CHROMATOGRAM

**Retention time:** 24

---

#### OTHER SUBSTANCES

**Simultaneous:** acetic acid, citric acid, dextrose, EtOH, fructose, lactic acid, malic acid, MeOH, tartaric acid

---

#### REFERENCE

*Keystone Scientific Catalog*, 1993-4, p. 45.

---

#### SAMPLE

**Matrix:** solutions

---

**HPLC VARIABLES****Column:** Hamilton PRP-X300**Mobile phase:** MeCN:0.5 mM sulfuric acid 10:90**Flow rate:** 3**Injection volume:** 1**Detector:** RI

---

**OTHER SUBSTANCES****Simultaneous:** i-butanol, n-butanol, s-butanol, t-butanol, EtOH, isopropanol, MeOH, n-propanol

---

**REFERENCE***Keystone Scientific Catalog, 1993-4, p. 23.*

---

**SAMPLE****Matrix:** solutions

---

**HPLC VARIABLES****Column:** Shodex Sugar SP 0810P and SP 0810**Mobile phase:** water**Column temperature:** 80**Flow rate:** 0.5**Detector:** RI

---

**CHROMATOGRAM****Retention time:** 27

---

**OTHER SUBSTANCES****Simultaneous:** arabinose, dextrose, fructose, galactose, lactose, lactulose, mannitol, pullulan P-10, raffinose, sorbitol, stachyose, sucrose, xylitol

---

**REFERENCE****Majors,R.E.** Polymeric liquid chromatography column technology in Japan, *LC.GC*, **1993**, *11*, 778-788.

---

**SAMPLE****Matrix:** solutions

---

**HPLC VARIABLES****Column:** 100 × 7.8 Sarasep AL-1 (Sarasep, MetaChem)**Mobile phase:** 50 mg/L dicalcium EDTA**Column temperature:** 85**Flow rate:** 0.7**Detector:** RI

---

**CHROMATOGRAM****Retention time:** 2

---

**OTHER SUBSTANCES****Simultaneous:** EtOH, isoamyl alcohol, n-amyl alcohol

---

**REFERENCE***MetaChem Catalog, 1994, p. 65.*

---

**SAMPLE****Matrix:** solutions

---

**HPLC VARIABLES****Column:** RSpak DC-613 (Shodex, Phenomenex)**Mobile phase:** MeCN:water 80:20**Flow rate:** 1

Detector: RI

---

**CHROMATOGRAM**

Retention time: 4.5

---

**OTHER SUBSTANCES**

Simultaneous: meso-erythrite, arabite, xylite, mannite, sorbite

---

**REFERENCE**

Phenomenex Catalog, 1994, p. 1.109.

---


# Glycopyrrolate

Molecular formula:  $C_{19}H_{28}BrNO_3$

Molecular weight: 398.34

CAS Registry No.: 596-51-0

Merck Index: 4511



---

**SAMPLE**

Matrix: formulations

Sample preparation: Inject a 20  $\mu$ L aliquot.

---

**HPLC VARIABLES**

Column: 100  $\times$  4.6 Spheri-5 RP-8

Mobile phase: MeCN:buffer 45:55 (Buffer was 10 mM  $KH_2PO_4$  adjusted to pH 4.0 with 1 M KOH.)

Flow rate: 1

Injection volume: 20

Detector: UV 254

---

**CHROMATOGRAM**

Retention time: 11.0

Limit of detection: 6.9  $\mu$ g/mL

---

**OTHER SUBSTANCES**

Simultaneous: ondansetron

Noninterfering: degradation products

---

**KEY WORDS**

injections; saline

---

**REFERENCE**

Venkateshwaran,T.G.; King,D.T.; Stewart,J.T. HPLC determination of ondansetron-atropine and ondansetron-glycopyrrolate mixtures in 0.9% sodium chloride injection, *J.Liq.Chromatogr.*, **1995**, 18, 2647-2659.

---

**SAMPLE**

Matrix: urine

Sample preparation: Condition a 500 mg 14 mL 40  $\mu$ m CCX-2 cation-exchange SPE cartridge (Worldwide Monitoring) with two 2.5 mL aliquots of MeOH, two 2.5 mL aliquots of water, and two 2.5 mL aliquots of 100 mM pH 7.00 phosphate buffer, do not allow to dry. 5 mL Urine + 3 mL 100 mM pH 7.00 phosphate buffer + 12.5 ng mepenzolate + 5 mL water, centrifuge at 800 g for 5 min, add to the SPE cartridge, wash with 5 mL MeOH, wash with 5 mL water, dry under vacuum for 5 min, elute with 4 mL MeOH:500 mM pH 3.00 ammonium acetate 95:5 (all flow rates were 1-2 mL/min). Evaporate the eluate under a stream of nitrogen at 60°, reconstitute in 100  $\mu$ L MeOH, inject a 10  $\mu$ L aliquot.




**HPLC VARIABLES****Column:** 150 × 4.1 10 µm LiChroma (Chromatographic Specialties)**Mobile phase:** MeOH:50 mM pH 3.0 ammonium acetate 80:20**Flow rate:** 0.8**Injection volume:** 10**Detector:** MS, Sciex API III triple quadrupole, ion spray interface, split column effluent 95:5 before entering detector, nebulizing gas air at 550 kPa, collision gas argon, curtain gas nitrogen, positive-ion mode, *m/z* 318 and 116**CHROMATOGRAM****Retention time:** 2.3**Internal standard:** mepenzolate (*m/z* 340 and 130) (2.1)**Limit of detection:** 0.25 ng/mL**KEY WORDS**

SPE; horse

**REFERENCE**

Matassa, L.C.; Woodard, D.; Leavitt, R.K.; Firby, P.; Beaumier, P. Solid-phase extraction techniques for the determination of glycopyrrolate from equine urine by liquid chromatography-tandem mass spectrometry and gas chromatography-mass spectrometry, *J. Chromatogr.*, **1992**, 573, 43–48.

# Gonadorelin

**Molecular formula:** C<sub>55</sub>H<sub>75</sub>N<sub>17</sub>O<sub>13</sub>**Molecular weight:** 1182.31**CAS Registry No.:** 33515-09-2, 51952-41-1 (HCl), 52699-48-6 (sulfate)**Merck Index:** 5500**SAMPLE****Matrix:** blood

**Sample preparation:** Condition a 1 mL Analytichem weak cation-exchange (carboxymethylhydrogen form, CBA) SPE cartridge with 1 mL 1% trifluoroacetic acid in MeOH, 1 mL MeOH, and 2 mL water. Add 1 mL plasma to the SPE cartridge, rinse the tube with 1 mL water, add the rinse to the SPE cartridge, wash with 1 mL 1% trifluoroacetic acid in water, wash with 2 mL water, wash with 2 mL MeOH, elute with 2 mL 1% trifluoroacetic acid in MeOH. Evaporate the eluate to dryness under a stream of nitrogen, reconstitute the residue in 100 µL MeOH: buffer 50:50, inject a 5–75 µL aliquot. (Buffer was 5.7 g monochloroacetic acid, 2.0 g NaOH, and 0.2 g disodium EDTA in 1 L water, pH 3.2.) [Procedure was not necessarily validated for this compound.]; SPE

**HPLC VARIABLES****Column:** 250 × 2 5 µm Ultrasphere octyl

**Mobile phase:** Gradient. A was MeOH containing 10 mM sodium octanesulfonate. B was buffer containing 10 mM sodium octanesulfonate. A:B from 45:55 to 70:30 over 30 min, maintain at 70:30 for 1 h. (Buffer was 5.7 g monochloroacetic acid, 2.0 g NaOH, and 0.2 g disodium EDTA in 1 L water, pH 3.2.)

**Column temperature:** 60**Flow rate:** 0.3**Injection volume:** 5–75

**Detector:** F ex 390 em 470 following post-column reaction. The column effluent mixed with 400 mM NaOH pumped at 0.15 mL/min and 0.05% ninhydrin pumped at 0.05 mL/min and the mixture flowed through a 12 m  $\times$  0.33 mm i.d. reaction coil at 70° to the detector.

---

#### CHROMATOGRAM

**Retention time:** 22

**Limit of detection:** 100 fmole

---

#### OTHER SUBSTANCES

**Simultaneous:** adrenocorticotropin, angiotensin I, angiotensin II, angiotensin III, atrial natriuretic peptide, bombesin, bradykinin, somatoliberin, vasopressin

---

#### KEY WORDS

plasma; SPE; post-column reaction

---

#### REFERENCE

Rhodes, G.R.; Boppana, V.K. High-performance liquid chromatographic analysis of arginine-containing peptides in biological fluids by means of a selective post-column reaction with fluorescence detection, *J. Chromatogr.*, **1988**, *444*, 123–131.

---

#### SAMPLE

**Matrix:** formulations

---

#### HPLC VARIABLES

**Column:** 100  $\times$  5 Nucleosil 5 C8

**Mobile phase:** MeOH:buffer 23:77 (Buffer was 100 mM phosphoric acid adjusted to pH 3.0 with triethylamine.)

**Flow rate:** 1.5

**Detector:** UV 220

---

#### CHROMATOGRAM

**Retention time:** 23

---

#### OTHER SUBSTANCES

**Simultaneous:** impurities

---

#### REFERENCE

Storring, P.L.; Corran, P.H.; Gaines Das, R.E.; Calam, D.H. The International Reference Preparation of Gonadorelin for Bioassay: a comparison with different preparations of synthetic luteinizing hormone releasing hormone using physicochemical methods of analysis, different bioassays and immunoassay, *J. Endocrinol.*, **1982**, *95*, 95–103.

---

#### SAMPLE

**Matrix:** solutions

---

#### HPLC VARIABLES

**Column:** 150  $\times$  4.6 Zorbax ODS

**Mobile phase:** MeCN:water:pH 3.0 triethylamine phosphate buffer 14:43:43

**Flow rate:** 1.5

**Detector:** UV 210

---

#### CHROMATOGRAM

**Limit of detection:** 100 ng/mL

---

#### KEY WORDS

validation

---

#### REFERENCE

Bi, M.; Singh, J. Modified HPLC method for quantification of luteinizing hormone-releasing hormone (Abstract 3367), *Pharm. Res.*, **1997**, *14*, S585.

---

**SAMPLE****Matrix:** solutions

---

**HPLC VARIABLES****Column:** 125 × 4 5 μm LiChrospher 100 RP-18**Mobile phase:** MeCN:0.1% trifluoroacetic acid 16:84**Flow rate:** 1**Injection volume:** 20**Detector:** UV 214

---

**CHROMATOGRAM****Retention time:** 10

---

**OTHER SUBSTANCES****Simultaneous:** degradation products

---

**REFERENCE**

Hoitink,M.A.; Beijnen,J.H.; Bult,A.; van der Houwen,O.A.G.J.; Nijholt,J.; Underberg,W.J.M. Degradation kinetics of gonadorelin in aqueous solution, *J.Pharm.Sci.*, **1996**, 85, 1053–1059.

---

**SAMPLE****Matrix:** solutions

---

**HPLC VARIABLES****Column:** 125 × 4 5 μm Lichrosphere 100 RP-18**Mobile phase:** MeCN:0.1% trifluoroacetic acid 16:84**Flow rate:** 1**Detector:** UV 214

---

**OTHER SUBSTANCES****Simultaneous:** degradation products

---

**REFERENCE**

Hoitink,M.A.; Beijnen,J.H.; Boschma,M.U.S.; Bult,A.; Hop,E.; Nijholt,J.; Versluis,C.; Wiese,G.; Underberg,W.J.M. Identification of the degradation products of gonadorelin and three analogues in aqueous solution, *Anal.Chem.*, **1997**, 69, 4972–4978.

---

**SAMPLE****Matrix:** solutions

---

**HPLC VARIABLES****Column:** 300 × 3.9 10 μm μBondapak C18**Mobile phase:** Gradient. A was 0.1% phosphoric acid. B was MeCN:0.1% phosphoric acid 70:30. A:B from 95:5 to 30:70 over 20 min.**Flow rate:** 1**Detector:** UV 206 or RIA

---

**CHROMATOGRAM****Retention time:** 17

---

**OTHER SUBSTANCES****Simultaneous:** protirelin, somatostatin, substance P

---

**REFERENCE**

McDermott,J.R.; Smith,A.I.; Biggins,J.A.; Al-Noaemi,M.C.; Edwardson,J.A. Characterization and determination of neuropeptides by high-performance liquid chromatography and radioimmunoassay, *J.Chromatogr.*, **1981**, 222, 371–379.

---

**SAMPLE****Matrix:** solutions

**Sample preparation:** Cool in ice while mixing 200  $\mu$ L solution, 100  $\mu$ L 4 mM benzoin in 2-methoxyethanol, 100  $\mu$ L mercaptoethanol solution, and 200  $\mu$ L 2 M KOH, heat on a boiling water bath for 5 min, cool in ice-water for 2 min, add 200  $\mu$ L 4 M HCl:buffer 50:50, inject a 100  $\mu$ L aliquot. (Prepare mercaptoethanol solution by dissolving 780 mg  $\beta$ -mercaptoethanol and 2.52 g sodium sulfite in 80 mL water, make up to 100 mL with water. Prepare buffer by dissolving 12.11 g Tris in 80 mL water, adjusting pH to 9.2 with concentrated HCl, and making up to 100 mL with water.)

---

#### HPLC VARIABLES

**Column:** 300  $\times$  3.9 10  $\mu$ m  $\mu$ Bondapak phenyl

**Mobile phase:** Gradient. MeOH:water:500 mM pH 8.5 Tris-HCl buffer 50:35:15 for 2 min, to 80:5:15 over 24 min, maintain at 80:5:15 for 2 min.

**Flow rate:** 0.8

**Injection volume:** 100

**Detector:** F ex 325 em 425

---

#### CHROMATOGRAM

**Retention time:** 14.5-18.5

---

#### OTHER SUBSTANCES

**Simultaneous:** N- $\alpha$ -acetylarginine, agmatine, angiotensin I, angiotensin II, angiotensin III, arginine, argininosuccinic acid, bradykinin, canavanine, creatine, creatinine, guanidine, guandinoacetic acid, guanidinobutyric acid, guanidinopropionic acid, guanidinosuccinic acid, homocysteine, methylguanidine, neurotensin, phenylguanidine, taurocyamine, tuftsins

---

#### KEY WORDS

derivatization

---

#### REFERENCE

Kai,M.; Miyazaki,T.; Yamaguchi,M.; Ohkura,Y. High-performance liquid chromatography of guanidino compounds using benzoin as a pre-column fluorescent derivatization reagent, *J.Chromatogr.*, **1983**, 268, 417-424.

---

#### SAMPLE

**Matrix:** solutions

**Sample preparation:** Cool in ice while mixing 100  $\mu$ L of an aqueous solution, 50  $\mu$ L 5 mM benzoin in 2-methoxyethanol, 50  $\mu$ L mercaptoethanol solution, and 100  $\mu$ L 0.8 M KOH, heat on a boiling water bath for 1.5 min, add 100  $\mu$ L 1.6 M HCl:1 M pH 8.5 Tris-HCl buffer 50:50, inject a 100  $\mu$ L aliquot. (Prepare mercaptoethanol solution by dissolving 780 mg  $\beta$ -mercaptoethanol and 2.52 g sodium sulfite in 80 mL water, make up to 100 mL with water.)

---

#### HPLC VARIABLES

**Column:** 15  $\times$  4 (sic) 5  $\mu$ m LiChrosorb RP-18

**Mobile phase:** MeCN:50 mM pH 8.5 phosphate buffer 31:69

**Flow rate:** 0.8

**Injection volume:** 100

**Detector:** F ex 325 em 425

---

#### CHROMATOGRAM

**Retention time:** 22

---

#### OTHER SUBSTANCES

**Simultaneous:** angiotensin I, angiotensin II, angiotensin III, leupeptin acid, substance P, tuftsins

---

#### KEY WORDS

derivatization

---

#### REFERENCE

Kai,M.; Miyazaki,T.; Sakamoto,Y.; Ohkura,Y. Use of benzoin as pre-column fluorescence derivatization reagent for the high-performance liquid chromatography of angiotensins, *J.Chromatogr.*, **1985**, 322, 473-477.

---

**SAMPLE****Matrix:** solutions**Sample preparation:** Inject an aliquot of a solution in saline or Sorensen's buffer.

---

**HPLC VARIABLES****Column:** 150 × 4.6 5 µm Econosphere endcapped C18**Mobile phase:** MeCN:water 80:20 containing 0.1% trifluoroacetic acid**Detector:** UV 278

---

**CHROMATOGRAM****Retention time:** 5.2

---

**OTHER SUBSTANCES****Simultaneous:** impurities

---

**REFERENCE**

Miller, L.L.; Kolaskie, C.J.; Smith, G.A.; Rivier, J. Transdermal iontophoresis of gonadotropin releasing hormone (LHRH) and two analogues, *J.Pharm.Sci.*, **1990**, 79, 490–493.

---

**SAMPLE****Matrix:** solutions

---

**HPLC VARIABLES****Column:** 250 × 4.6 TSKgel ODS-120T**Mobile phase:** Gradient. A was MeOH:water 20:80 containing 0.05% trifluoroacetic acid. B was MeOH:water 50:50 containing 0.05% trifluoroacetic acid. A:B from 100:0 to 0:100 over 1 h.**Flow rate:** 1**Detector:** UV 220

---

**CHROMATOGRAM****Retention time:** 9

---

**OTHER SUBSTANCES****Simultaneous:** angiotensin I, angiotensin II, α-endorphin, β-endorphin, calcitonin (human), pro-tirelin (TRH), somatostatin

---

**REFERENCE**

*Varian Catalog*, **1993**, p. 182.

---

**SAMPLE****Matrix:** solutions

---

**HPLC VARIABLES****Column:** 200 × 3 Spherisorb S5ODS-2**Mobile phase:** Gradient. A was 0.05% phosphoric acid containing 0.5% (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>. B was MeCN. A:B from 82:18 to 64:36 over 25 min, maintain at 64:36 for 2.5 min, return to initial conditions over 1 min, re-equilibrate for 6.5 min. or Isocratic MeCN:0.05% phosphoric acid containing 0.5% (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> 24:76**Flow rate:** 0.5**Detector:** UV 210

---

**CHROMATOGRAM****Retention time:** 9 (gradient), 2.5 (isocratic)

---

**OTHER SUBSTANCES****Simultaneous:** busarelin, deslorelin, goserelin, leuprolide, nafarelin

---

**KEY WORDS**

comparison with capillary electrophoresis

---

**REFERENCE**

Corran,P.H.; Sutcliffe,N. Identification of gonadorelin (LHRH) derivatives: comparison of reversed-phase high-performance liquid chromatography and micellar electrokinetic chromatography, *J.Chromatogr.*, **1993**, 636, 87-94.

---

**SAMPLE**

**Matrix:** tissue

**Sample preparation:** Condition a Bond Elut C18 SPE cartridge with 3 mL water and 3 mL MeCN (in this order ?). Homogenize 400 mg brain tissue with 2 mL 100 mM HCl, add 20  $\mu$ L 10  $\mu$ M IS, add 2 mL acetone, mix, centrifuge at 2450 g for 15 min. Remove the supernatant and add it to 220  $\mu$ L 1 M sodium bicarbonate and 500  $\mu$ L 100 mM disodium EDTA, centrifuge at 2450 g for 15 min. Remove the supernatant and evaporate it to remove the acetone, dilute the aqueous residue with 2 mL water, add to the SPE cartridge. wash with 1 mL water, wash with 3 mL 100 mM HCl, wash with two 3 mL portions of dichloromethane, wash with 1 mL water, wash with 2 mL 100 mM pH 8.0 phosphate buffer, wash with 2 mL water, elute with 2 mL MeCN:100 mM pH 2.3 phosphate buffer 70:30. Evaporate the eluate under reduced pressure, make up to 400  $\mu$ L with water, inject a 100  $\mu$ L aliquot.

---

**HPLC VARIABLES**

**Column:** 200  $\times$  4.5  $\mu$ m TSKgel ODS-120T (Tosoh)

**Mobile phase:** Gradient. A was MeCN:300 mM pH 2.3 sodium phosphate buffer:water 1:20:79.

B was MeCN:300 mM pH 2.3 sodium phosphate buffer:water 60:20:20. A:B from 90:10 to 55:45 over 33 min, maintain at 55:45 for 7 min, to 0:100 (step gradient), maintain at 0:100.

**Flow rate:** 1

**Injection volume:** 100

**Detector:** F ex 325 em 435 following post-column reaction. The column effluent mixed with 2 mM benzoin in 1.6 M KOH containing 700 mM 2-mercaptoethanol and this mixture flowed through a 15 m  $\times$  0.33 mm ID PTFE coil at 76  $\pm$  1°. The effluent from this coil mixed with 500 mM Tris containing 2.1 M HCl pumped at 0.4 mL/min and this mixture flowed to the detector.

---

**CHROMATOGRAM**

**Retention time:** 29.2

**Internal standard:** [D-Phe<sup>11</sup>]-neurotensin (40.0)

**Limit of detection:** 0.5 pmole

---

**OTHER SUBSTANCES**

**Extracted:** bradykinin, dynorphin 1-8, kallidin, leucine enkephalin-Arg, methionine enkephalin-Arg-Gly-Leu, methionine enkephalin-Arg-Phe,  $\alpha$ -neoendorphin,  $\beta$ -neoendorphin, neurotensin, substance P, vasopressin

---

**KEY WORDS**

post-column reaction; rat; brain; SPE

---

**REFERENCE**

Ohno,M.; Kai,M.; Ohkura,Y. High-performance liquid chromatographic determination of substance P-like arginine-containing peptide in rat brain by on-line post-column fluorescence derivatization with benzoin, *J.Chromatogr.*, **1989**, 490, 301-310.

---

**SAMPLE**

**Matrix:** tissue

**Sample preparation:** Tissue homogenate + MeCN, vortex for 10 s, centrifuge at 10000 g for 15 min. Remove the supernatant and evaporate it to dryness under a stream of nitrogen, reconstitute the residue in 100  $\mu$ L mobile phase, inject an aliquot.

---

**HPLC VARIABLES**

**Column:** 250  $\times$  4.10  $\mu$ m Lichrosorb RP-18

**Mobile phase:** Gradient. MeCN:0.6% aqueous ethanolamine, pH 3.0 14:86 for 5 min, to 30:70 over 8 min, maintain at 30:70 for 7 min, re-equilibrate at initial conditions for 5 min.

**Flow rate:** 1

**Detector:** UV 254

**CHROMATOGRAM****Retention time:** 10**OTHER SUBSTANCES****Extracted:** degradation products**KEY WORDS**

rabbit; rectal mucosa; vaginal mucosa; nasal mucosa

**REFERENCE**

Han,K.; Park,J.S.; Chung,Y.B.; Lee,M.J.; Moon,D.C.; Robinson,J.R. Identification of enzymatic degradation products of luteinizing hormone releasing hormone (LHRH)/[D-Ala6] LHRH in rabbit mucosal homogenates, *Pharm.Res.*, **1995**, *12*, 1539–1544.

---

# Gonadotropin

**Molecular weight:** ca. 39500**CAS Registry No.:** 9002-71-3**Merck Index:** 2273

---

**SAMPLE****Matrix:** solutions

---

**HPLC VARIABLES****Column:** 300 × 4 10 µm µBondapak alkylphenyl**Mobile phase:** Gradient. A was 100 mM pH 7.0 ammonium acetate. B was MeCN:water 60:40 containing 15 mM trifluoroacetic acid, pH 2.0. A:B from 100:0 to 0:100 over 90 min.**Flow rate:** 1.2**Detector:** UV 278

---

**CHROMATOGRAM****Retention time:** 30 (α1), 32 (α2), 33 (β1), 34 (β2) (subunits)

---

**REFERENCE**

Grego,B.; Hearn,M.T.W. High-performance liquid chromatography of amino acids, peptides and proteins. LXIII. Reversed-phase high-performance liquid chromatographic characterisation of several polypeptide and protein hormones, *J.Chromatogr.*, **1984**, *336*, 25–40.

---

**SAMPLE****Matrix:** solutions

---

**HPLC VARIABLES****Column:** 250 × 4.6 Vydac C4 300 A no. 214TP54**Mobile phase:** Gradient. A was 0.1% trifluoroacetic acid in water. B was 0.1% trifluoroacetic acid in MeCN. A:B from 100:0 to 40:60 over 90 min.**Flow rate:** 1**Detector:** UV 220

---

**CHROMATOGRAM****Retention time:** 50 (α-1), 52 (α-2), 50 (β-1), 54 (β-2) (subunits)

---

**REFERENCE**

Pollak,S.; Halpine,S.; Chait,B.T.; Birken,S. High resolution high performance liquid chromatography fingerprinting of purified human chorionic gonadotropin demonstrates that oxidation is a cause of hormone heterogeneity, *Endocrinology*, **1990**, *126*, 199–208.


# Goserelin

**Molecular formula:**  $C_{59}H_{84}N_{18}O_{14}$

**Molecular weight:** 1269.43

**CAS Registry No.:** 65807-02-5

**Merck Index:** 4547



## SAMPLE

**Matrix:** solutions

## HPLC VARIABLES

**Column:** 125 × 4.5 μm Lichrosphere 100 RP-18

**Mobile phase:** MeCN:0.1% trifluoroacetic acid 22:78

**Flow rate:** 1

**Detector:** UV 214

## OTHER SUBSTANCES

**Simultaneous:** degradation products

**Also analyzed:** triptorelin

## REFERENCE

Hoitink, M.A.; Beijnen, J.H.; Boschma, M.U.S.; Bult, A.; Hop, E.; Nijholt, J.; Versluis, C.; Wiese, G.; Underberg, W.J.M. Identification of the degradation products of gonadorelin and three analogues in aqueous solution, *Anal. Chem.*, **1997**, 69, 4972–4978.


# Gossypol

**Molecular formula:**  $C_{30}H_{30}O_8$

**Molecular weight:** 518.56

**CAS Registry No.:** 303-45-7

**Merck Index:** 4549



## SAMPLE

**Matrix:** blood

**Sample preparation:** 400 μL serum + 500 μL saturated disodium EDTA, mix, let stand for 10 min, adjust to pH 8.0 with concentrated NaOH solution using a micro-electrode, add 50 μL 1 g/mL L-phenylalanine methyl ester in MeCN, let stand for 10 min, adjust pH to 7.00 with concentrated sulfuric acid, add 2 mL ether, vortex, centrifuge, repeat extraction. Combine the organic layers and evaporate them to dryness under reduced pressure, reconstitute the residue in 500 μL MeCN, inject a 50 μL aliquot.

## HPLC VARIABLES

**Column:** 250 × 4.5 μm Hypersil ODS



**Mobile phase:** MeCN:THF:buffer 76:2:22 (Buffer was 10 mM  $\text{KH}_2\text{PO}_4$  adjusted to pH 2.35 with phosphoric acid.)

**Flow rate:** 2.5

**Injection volume:** 50

**Detector:** UV 250

#### CHROMATOGRAM

**Retention time:** 11 (-), 17 (+)

**Limit of detection:** 30 ng/mL

#### KEY WORDS

serum; derivatization; chiral

#### REFERENCE

Matlin, S.A.; Belenguer, A.; Vince, P.M.; Stein, R. Analysis of gossypol enantiomers in human serum, *J. Liq. Chromatogr.*, **1990**, *13*, 2261–2268.


## Gramicidin

**Molecular formula:**  $\text{C}_{80}\text{H}_{92}\text{N}_{12}\text{O}_{10}$

**Molecular weight:** 1141.47

**CAS Registry No.:** 1405-97-6,  
113-73-5 (gramicidin S)

**Merck Index:** 4552



#### SAMPLE

**Matrix:** saliva

**Sample preparation:** Mix saliva with an equal volume of EtOH, centrifuge.

#### HPLC VARIABLES

**Column:** 200 × 3 5  $\mu\text{m}$  Nucleosil C8

**Mobile phase:** MeCN:water:phosphoric acid 47.5:52.5:0.01

**Column temperature:** 70

**Flow rate:** 2.5

**Injection volume:** 20

**Detector:** UV 220

#### CHROMATOGRAM

**Retention time:** 13 (valin-gramicidin A)

**Limit of detection:** 1  $\mu\text{g/mL}$

#### KEY WORDS

pharmacokinetics

#### REFERENCE

Kreuzig, F.; Nahler, G. Salivary levels of gramicidin after use of a tyrothricin lozenge and a tyrothricin gargle/mouth-wash, *Int. J. Clin. Pharmacol. Res.*, **1983**, *3*, 65–70.

#### SAMPLE

**Matrix:** solutions

**Sample preparation:** Inject a 2  $\mu\text{L}$  aliquot.

#### HPLC VARIABLES

**Column:** 300 × 7.8 Ultrastaygel 1000 Å (Waters)

**Mobile phase:** THF  
**Flow rate:** 1  
**Injection volume:** 2  
**Detector:** F ex 297 em 330

---

**CHROMATOGRAM**

**Retention time:** 7.9 (dimers), 8.4 (monomer)


---

**REFERENCE**

Bañó,M.C.; Braco,L.; Abad,C. New high-performance liquid chromatography-based methodology for monitoring the conformational transitions of self-associating hydrophobic peptides, incorporated into liposomes, *J.Chromatogr.*, **1988**, *458*, 105–116.

---

# Granisetron



**Molecular formula:**  $C_{18}H_{24}N_4O$   
**Molecular weight:** 312.41  
**CAS Registry No.:** 109889-09-0, 107007-99-8 (HCl)  
**Merck Index:** 4557  
**Lednicer No.:** 5 118

---

**SAMPLE**

**Matrix:** blood

**Sample preparation:** Filter (Amicon Centricon-10 microconcentrator, 10000 daltons molecular weight cutoff) 150  $\mu$ L plasma while centrifuging at 5° at 5000 g for 100 min, inject a 10  $\mu$ L aliquot of the ultrafiltrate.

---

**HPLC VARIABLES**

**Column:** 100  $\times$  4.6 5  $\mu$ m Spheri-5 silica  
**Mobile phase:** MeCN:25 mM pH 4.2 sodium acetate 40:60  
**Flow rate:** 1  
**Injection volume:** 10  
**Detector:** UV 305

---

**CHROMATOGRAM**

**Retention time:** 3.4  
**Limit of detection:** 19 ng/mL

---

**KEY WORDS**

plasma; guinea pig; ultrafiltrate

---

**REFERENCE**

Capacio,B.R.; Byers,C.E.; Jackson,T.K.; Matthews,R.L. An HPLC method for the determination of granisetron in guinea pig plasma, *J.Anal.Toxicol.*, **1993**, *17*, 151–155.

---

**SAMPLE**

**Matrix:** blood

**Sample preparation:** Condition a 100 mg Bond Elut C2 SPE cartridge with two 1 mL portions of MeOH, 1 mL water, and two 1 mL portions of buffer. 1 mL Plasma + 100  $\mu$ L 40 ng/mL IS in water + 500  $\mu$ L buffer, add to the SPE cartridge, wash with 1 mL MeCN:water 40:60, remove all wash solvent, elute with 800  $\mu$ L MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 50°. Add 30  $\mu$ L 10% trimethylsilyldiazomethane in hexane and 30  $\mu$ L 2% N,N-diisopropylethylamine in MeOH to the residue, heat at 50° for 20 min, cool to room temperature, evaporate to dryness under a stream of nitrogen at 50°, reconstitute in 300  $\mu$ L MeOH: water 10:90, centrifuge at 1700 g for 5 min, inject a 150  $\mu$ L aliquot. (Phosphate buffer was 4.33 g  $Na_2HPO_4$  and 3.04 g  $NaH_2PO_4 \cdot 2H_2O$  in 50 mL water.)

---

**HPLC VARIABLES****Guard column:** 15 × 3.2 NewGuard RP-18**Column:** 250 × 4.6 5 µm Develosil ODS-5 (Nomura Chemical)**Mobile phase:** MeOH:buffer 30:70 (Buffer was 15.4 g ammonium acetate and 20 mL tetra-n-butylammonium hydroxide in 1.7 L water, adjust pH to 4.70 with glacial acetic acid, make up to 2 L with water.)**Column temperature:** 45**Flow rate:** 1**Injection volume:** 150**Detector:** F ex 310 em 420

---

**CHROMATOGRAM****Retention time:** 9.5**Internal standard:** 2-methyl-M-(endo-9-methyl-9-azabicyclo[3.3.1]non-3-yl)-2H-indazole-3-carboxamide hydrochloride (6)**Limit of detection:** 42 pg/mL

---

**OTHER SUBSTANCES****Extracted:** metabolites

---

**KEY WORDS**plasma; SPE; derivatization

---

**REFERENCE**

Kudoh,S.; Sato,T.; Okada,H.; Kumakura,H.; Nakamura,H. Simultaneous determination of granisetron and 7-hydroxygranisetron in human plasma by high-performance liquid chromatography with fluorescence detection, *J.Chromatogr.B*, **1994**, 660, 205–210.

---

**SAMPLE****Matrix:** blood

**Sample preparation:** Condition a C2 SPE cartridge (Analytichem) with 1 mL MeOH, 1 mL water, and 1 mL 1 M pH 7.0 phosphate buffer. 1 mL Plasma + 50 µL water + 50 µL 100 ng/mL IS in water + 500 µL 1 M pH 7.0 phosphate buffer, add immediately to SPE cartridge, wash with 1 mL water, wash with 1 mL MeCN:water 40:60, remove wash solvent completely, elute with 1 mL MeOH, elute with 1 mL MeOH:trifluoroacetic acid 99:1. Combine the eluates and evaporate them to dryness under a stream of nitrogen at 40°, reconstitute the residue in 200 µL MeOH:water 10:90, vortex for 30 s, centrifuge at 2000 g for 5 min, transfer to a fresh vial, centrifuge at 2000 g for 5 min, inject a 10–65 µL aliquot.

---

**HPLC VARIABLES****Guard column:** 30 × 2.1 C8 (ABI Instruments)**Column:** 150 × 2.1 Zorbax Rx C8**Mobile phase:** MeCN:buffer 19:81 (Buffer was 0.95 g sodium hexanesulfonate in 405 mL 100 mM pH 4.7 acetate buffer.)**Column temperature:** 30**Flow rate:** 0.3**Injection volume:** 10–65**Detector:** E, ESA, E1 0.15 V, E2 0.35 V (measuring electrode), guard cell 0.4 V (before injector) followed by F ex 305 em 360

---

**CHROMATOGRAM****Retention time:** 17 (F)**Internal standard:** 8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1-methyl-1H-indazole-3-carboxylate (BRL 43704) (21) (F)**Limit of quantitation:** 0.1 ng/mL

---

**OTHER SUBSTANCES****Extracted:** metabolites

---

**KEY WORDS**

plasma; SPE; fluorescence detection for granisetron and some metabolites; electrochemical detection for other metabolites

---

**REFERENCE**

Boppana,V.K. Simultaneous determination of granisetron and its 7-hydroxy metabolite in human plasma by reversed-phase high-performance liquid chromatography utilizing fluorescence and electrochemical detection, *J.Chromatogr.A*, **1995**, 692, 195–202.

---

**SAMPLE**

**Matrix:** blood

**Sample preparation:** 500  $\mu$ L Plasma + 7  $\mu$ g IS, vortex for 10 s, add 1.5 mL toluene, add 250  $\mu$ L buffer, shake for 20 min, centrifuge at 3000 g for 10 min. Remove 1 mL of the organic layer and evaporate it to dryness under a stream of nitrogen at 37°, reconstitute the residue in 40  $\mu$ L mobile phase, vortex for 10 s, inject a 20  $\mu$ L aliquot.

---

**HPLC VARIABLES**

**Column:** 250  $\times$  4.6 10  $\mu$ m Spherisorb CN

**Mobile phase:** MeCN:buffer 15:85 (Buffer was 100 mM NaH<sub>2</sub>PO<sub>4</sub> adjusted to pH 4.5 with orthophosphoric acid.)

**Flow rate:** 2

**Injection volume:** 20

**Detector:** F ex 305 em 365

---

**CHROMATOGRAM**

**Retention time:** 6.64

**Internal standard:** N-(1-naphthyl)ethylenediamine dihydrochloride (3.60)

**Limit of detection:** 0.1 ng/mL

**Limit of quantitation:** 0.3 ng/mL

---

**OTHER SUBSTANCES**

**Noninterfering:** metabolites, anthracyclines, cimetidine, cisplatin, dexamethasone, etoposide, fluorouracil, methotrexate, methylprednisolone, ondansetron

---

**KEY WORDS**

plasma

---

**REFERENCE**

Pinguet,F.; Bressolle,F.; Martel,P.; Salabert,D.; Astre,C. High-performance liquid chromatographic determination of granisetron in human plasma, *J.Chromatogr.B*, **1996**, 675, 99–105.

---

**SAMPLE**

**Matrix:** blood, pleural effusion, urine

**Sample preparation:** Mix 500  $\mu$ L serum, pleural effusion, or urine with 100  $\mu$ L IS solution and 400  $\mu$ L pH 9.0 ammonium acetate. Add to an Extrelut-1 SPE cartridge. After 15 min, elute with 3 mL and 4 mL portions of dichloromethane. Evaporate the eluate to dryness under a stream of nitrogen at 40°, reconstitute the residue with 100  $\mu$ L mobile phase, inject an aliquot.

---

**HPLC VARIABLES**

**Column:** 250  $\times$  4.6 10  $\mu$ m LiChroCART LiChrospher 100 CN

**Mobile phase:** MeCN:100 mM pH 3.5 acetate buffer 30:70

**Column temperature:** 40

**Flow rate:** 1

**Injection volume:** 20

**Detector:** F ex 290 em 365

---

**CHROMATOGRAM**

**Retention time:** 11.3

**Internal standard:** BRL 43693A (Smith Kline Beecham) (9.5)

**Limit of detection:** 250 pg/mL

**Limit of quantitation:** 2 ng/mL

---

**OTHER SUBSTANCES**

**Extracted:** etoposide

**Simultaneous:** domperidone, metoclopramide, ondansetron

**Noninterfering:** cisplatin, carboplatin, dexamethasone

---

**KEY WORDS**

serum; SPE; pharmacokinetics

---

**REFERENCE**

Wada,I.; Satoh,M.; Takeda,T.; Nakabayashi,T.; Honma,T.; Saitoh,H.; Takada,M.; Hirano,K. A rapid assay of granisetron in biological fluids from cancer patients, *Biol.Pharm.Bull.*, **1998**, 21, 535-537.

---

**SAMPLE**

**Matrix:** blood, urine

**Sample preparation:** 1 mL Plasma or urine + 100  $\mu$ L IS in water + 500  $\mu$ L 100 mM pH 12 phosphate buffer + 3 mL toluene, shake mechanically for 30 min, centrifuge. Remove the organic layer and evaporate it to dryness under a stream of nitrogen at 60°, reconstitute the residue in 100  $\mu$ L mobile phase, inject an 80  $\mu$ L aliquot.

---

**HPLC VARIABLES**

**Guard column:** 50 mm long unspecified

**Column:** 250 X 4.5 10  $\mu$ M Apex CN

**Mobile phase:** MeOH:buffer 97:3 (Buffer was 50 mM sodium acetate containing 0.25% triethylamine adjusted to pH 6.0.)

**Flow rate:** 1

**Injection volume:** 80

**Detector:** F ex 305 em 360

---

**CHROMATOGRAM**

**Retention time:** 13.5

**Internal standard:** endo-1-methyl-O-(9-methyl-9-azabicyclo(3,3,1)non-3-yl)-1H-indazole-3-carboxylate (BRL 43704) (19.2)

**Limit of detection:** 0.1 ng/mL

---

**KEY WORDS**

plasma; human; rat; dog

---

**REFERENCE**

Clarkson,A.; Coates,P.E.; Zussman,B.D. A specific h.p.l.c. method for the determination of BRL 43694 in plasma and urine, *Br.J.Clin.Pharmacol.*, **1988**, 25, 136P.

---

**SAMPLE**

**Matrix:** formulations

**Sample preparation:** Dilute 1-mg granisetron hydrochloride injection with 0.9% NaCl or 5% dextrose to a granisetron concentration of 100  $\mu$ g/mL, inject a 20  $\mu$ L aliquot of the solution.

---

**HPLC VARIABLES**

**Column:** 250  $\times$  4.6 5  $\mu$ m Spherisorb Cyano

**Mobile phase:** MeCN:100 mM NaH<sub>2</sub>PO<sub>4</sub> 15:85

**Flow rate:** 2

**Injection volume:** 20

**Detector:** UV 302

---

**CHROMATOGRAM**

**Retention time:** 9.1

---

**OTHER SUBSTANCES**

**Simultaneous:** degradation products

---

**KEY WORDS**

injections; stability-indicating

---

**REFERENCE**

Quercia,R.A.; Zhang,J.; Fan,C.; Chow,M.S.S. Stability of granisetron hydrochloride in polypropylene syringes, *Am.J.Health-Syst.Pharm.*, **1996**, 53, 2744–2746.

---

**SAMPLE**

**Matrix:** formulations

**Sample preparation:** Filter (0.2  $\mu\text{m}$  nylon), inject a 50  $\mu\text{L}$  aliquot of the filtrate.

---

**HPLC VARIABLES**

**Column:** 250  $\times$  4.6 5  $\mu\text{m}$  Accubond CN (J & W)

**Mobile phase:** MeCN:buffer 60:40 (Buffer was 20 mM  $\text{KH}_2\text{PO}_4$  containing 5 mM octanesulfonic acid, adjusted to pH 6.0 with 1 M NaOH.)

**Flow rate:** 1.5

**Injection volume:** 50

**Detector:** UV 305

---

**CHROMATOGRAM**

**Retention time:** 7.5

---

**KEY WORDS**

injections; saline; 5% dextrose; stability-indicating

---

**REFERENCE**

Chung,K.C.; Chin,M.A.; Gill,M.A. Stability of granisetron hydrochloride in a disposable elastomeric infusion device, *Am.J.Health-Syst.Pharm.*, **1995**, 52, 1541–1543.

---

**SAMPLE**

**Matrix:** formulations

**Sample preparation:** Inject a 20  $\mu\text{L}$  aliquot.

---

**HPLC VARIABLES**

**Column:** 250  $\times$  4.6 5  $\mu\text{m}$  Spherisorb CN

**Mobile phase:** MeCN:100 mM pH 4.5  $\text{NaH}_2\text{PO}_4$  15:85

**Injection volume:** 20

**Detector:** UV 300

---

**CHROMATOGRAM**

**Retention time:** 6.8

**Internal standard:** propylparaben (3.3)

---

**OTHER SUBSTANCES**

**Simultaneous:** dexamethasone, methylprednisolone

---

**KEY WORDS**

injections; 5% dextrose; saline; water

---

**REFERENCE**

Pinguet,F.; Rouanet,P.; Martel,P.; Fabbro,M.; Salabert,D.; Astre,C. Compatibility and stability of granisetron, dexamethasone, and methylprednisolone in injectable solutions, *J.Pharm.Sci.*, **1995**, 84, 267–268.

---

**SAMPLE**

**Matrix:** formulations

**Sample preparation:** Dilute with mobile phase, inject an aliquot.

---

**HPLC VARIABLES**

**Column:** 250  $\times$  4.6 10  $\mu\text{m}$  cyano

**Mobile phase:** MeCN:100 mM  $\text{NaH}_2\text{PO}_4$  20:80 adjusted to pH 4.2 with phosphoric acid

**Flow rate:** 2

**Injection volume:** 20

**Detector:** UV 300

---

**CHROMATOGRAM**

**Retention time:** 5.60

---

**OTHER SUBSTANCES**

**Simultaneous:** dexamethasone (UV 228)

---

**KEY WORDS**

stability-indicating; injections; saline; 5% dextrose; apple juice; orange juice; soft drinks

---

**REFERENCE**

Mayron,D.; Gennaro,A.R. Stability and compatibility of granisetron hydrochloride in i.v. solutions and oral liquids and during simulated Y-site injection with selected drugs, *Am.J.Health-Syst.Pharm.*, **1996**, 53, 294–304.

---

**SAMPLE**

**Matrix:** solutions

---

**HPLC VARIABLES**

**Column:** 150 × 3.9 5 µm Symmetry C8 (Waters)

**Mobile phase:** MeCN:20 mM sodium dihydrogen phosphate 20:80

**Flow rate:** 1

**Injection volume:** 20

**Detector:** UV 307

---

**CHROMATOGRAM**

**Retention time:** 4.5

---

**OTHER SUBSTANCES**

**Simultaneous:** doxorubicin (11.2)

---

**REFERENCE**

Zhang,H.; Ye,L.; Stewart,J.T. HPLC determinations of doxorubicin with selected medications in 0.9% sodium chloride injection USP, *J.Liq.Chromatogr.Rel.Technol.*, **1998**, 21, 2375–2385.

---

**SAMPLE**

**Matrix:** solutions

**Sample preparation:** Inject an aliquot of an aqueous solution.

---

**HPLC VARIABLES**

**Column:** 250 × 4 Nucleosil C18

**Mobile phase:** MeOH:THF:buffer 30:5:65 (Buffer was 100 mM triethylamine adjusted to pH 3.0 with nitric acid.)

**Flow rate:** 0.8

**Injection volume:** 20

**Detector:** UV 254

---

**CHROMATOGRAM**

**Retention time:** 6.37

---

**OTHER SUBSTANCES**

**Simultaneous:** ondansetron, tropisetron

---

**REFERENCE**

Barbato,F.; Immacolata La Rotonda,M.; Quaglia,F. Retention behaviour of anti-emetic serotonin antagonists in reversed phase high performance liquid chromatography, *Farmaco*, **1995**, 50, 875–880.


# Grepafloxacin

**Molecular formula:**  $C_{19}H_{22}FN_3O_3$

**Molecular weight:** 359.40

**CAS Registry No.:** 119914-60-2, 146863-02-7 ( $\pm$ ),  
161967-81-3 ( $(\pm)$  HCl)

**Merck Index:** 4567



## SAMPLE

**Matrix:** blood

**Sample preparation:** Extract 200  $\mu$ L plasma with dichloromethane:n-butanol 95:5 and evaporate to dryness. Treat the organic layer residue with Mosher's acid chloride (R-(-) or S-(+)- $\alpha$ -methoxy- $\alpha$ -trifluoromethylphenylacetic acid chloride) and triethanolamine in dichloromethane for 1 hr. Reconstitute, inject an aliquot.

## HPLC VARIABLES

**Column:** 150  $\times$  3.2 5  $\mu$ m ODS

**Mobile phase:** MeCN:0.2% phosphoric acid 70:30

**Column temperature:** 35

**Detector:** F ex 290 em 470

## CHROMATOGRAM

**Retention time:** 12.7 (S-(-)), 13.5 (R-(+))

**Internal standard:** ciprofloxacin (7.4)

**Limit of quantitation:** 25 ng/mL

## KEY WORDS

derivatization; chiral; plasma

## REFERENCE

Tata,P.N.V.; Bramer,S.L. Enantiomeric assay of grepafloxacin in plasma (Abstract 4162), *Pharm.Res.*, **1997**, *14*, S684.

# Griseofulvin


**Molecular formula:**  $C_{17}H_{17}ClO_6$

**Molecular weight:** 352.8

**CAS Registry No.:** 126-07-8

**Merck Index:** 4571

**Lednicer No.:** 1 314



## SAMPLE

**Matrix:** blood

**Sample preparation:** 100  $\mu$ L Plasma + 100  $\mu$ L p-phenylphenol in MeCN, vortex, centrifuge, inject a 20  $\mu$ L aliquot of the supernatant.

## HPLC VARIABLES

**Column:** 150 mm long 5  $\mu$ m Novapack

**Mobile phase:** MeCN:0.1 M acetic acid, pH 3.5 45:55

**Flow rate:** 1

**Injection volume:** 20

**Detector:** UV 290

## CHROMATOGRAM

**Retention time:** 3.0



**Internal standard:** p-phenylphenol (4.5)

**Limit of detection:** 50 ng/mL

---

## KEY WORDS

rat; plasma; pharmacokinetics

---

## REFERENCE

Vudathala,G.K.; Rogers,J.A. Oral bioavailability of griseofulvin from aged griseofulvin: lipid coprecipitates: in vivo studies in rats, *J.Pharm.Sci.*, **1992**, *81*, 1166–1169.

---

## SAMPLE

**Matrix:** blood, CSF, gastric contents, urine

**Sample preparation:** 200  $\mu$ L Serum, urine, CSF, or gastric fluid + 300  $\mu$ L reagent. Flush column A to waste with 500  $\mu$ L 500 mM ammonium sulfate, inject sample onto column A, flush column A to waste with 500  $\mu$ L 500 mM ammonium sulfate, backflush the contents of column A onto column B with mobile phase, monitor the effluent from column B. (Reagent was 8.05 M guanidine HCl and 1.02 M ammonium sulfate in water.)

---

## HPLC VARIABLES

**Column:** A 40  $\mu$ m preparative grade C18 (Analytichem); B 75  $\times$  2.1 pellicular C18 (Whatman) + 250  $\times$  4.6 5  $\mu$ m C8 end-capped (Whatman)

**Mobile phase:** Gradient. A was 50 mM pH 4.5  $\text{KH}_2\text{PO}_4$ . B was MeCN:isopropanol 80:20. A:B 90:10 for 1 min, to 30:70 over 20 min.

**Column temperature:** 50

**Flow rate:** 1.5

**Detector:** UV 220

---

## CHROMATOGRAM

**Retention time:** 13.51

**Internal standard:** heptanophenone (19)

---

## OTHER SUBSTANCES

**Extracted:** acetaminophen, allobarbitol, azinphos, barbitol, brallobarbitone, bromazepam, butethal, caffeine, carbamazepine, carbaryl, cephaloridine, chloramphenicol, chlordiazepoxide, chlorothiazide, chlorvinphos, clothiapine, cocaine, coomassie blue, desipramine, diazepam, diphenhydramine, dipipanone, ethylbromphos, flufenamic acid, formothion, indomethacin, lidocaine, lorazepam, malathion, medazepam, midazolam, oxazepam, paraoxon, penicillin G, pentobarbitol, prazepam, propoxyphene, prothiophos, quinine, salicylic acid, secobarbitol, strychnine, sulfamethoxazole, theophylline, thiopental, thioridazine, trimethoprim

---

## KEY WORDS

serum; column-switching

---

## REFERENCE

Kruger,P.B.; Albrecht,C.F.De V.; Jaarsveld,P.P. Use of guanidine hydrochloride and ammonium sulfate in comprehensive in-line sorption enrichment of xenobiotics in biological fluids by high-performance liquid chromatography, *J.Chromatogr.*, **1993**, *612*, 191–198.

---

## SAMPLE

**Matrix:** blood, urine

**Sample preparation:** Add 1 mL whole blood or urine to Toxi-Tube A (Toxi-Lab, Irvine CA), add 3 mL water, mix by gentle inversion for 5 min, centrifuge at 1500 g for 5 min. Remove the organic layer and evaporate it to dryness under a stream of nitrogen at 40°, reconstitute the residue with 50  $\mu$ L MeCN:water 50:50, vortex for 10 s, centrifuge at 7500 g for 2 min, inject a 10 (urine) or 30 (blood)  $\mu$ L aliquot. (The detector wavelength shown is the wavelength of maximum absorbance. This will not necessarily be the optimal wavelength for the separation. Multiple wavelengths from 200–350 nm can be scanned using a diode-array detector. Otherwise, 220 nm may be a reasonable choice for initial work. Matrix may interfere.)

---

## HPLC VARIABLES

**Guard column:** 20 mm long Symmetry C18

**Column:** 250 × 4.6 5 µm Symmetry C8 (Waters)

**Mobile phase:** Gradient. A was 50 mM pH 3.8 sodium phosphate buffer. B was MeCN. A:B 85:15 for 6.5 min, 65:35 for 18.5 min, 20:80 for 3 min (step gradient), re-equilibrate at initial conditions for 7 min.

**Column temperature:** 30

**Flow rate:** 1 for 6.5 min, to 1.5 over 18.5 min, maintain at 1.5 for 3 min (re-equilibrate at 1.5 mL/min)

**Injection volume:** 10-30

**Detector:** UV 292.6

---

#### CHROMATOGRAM

**Retention time:** 18.392

---

#### KEY WORDS

whole blood

---

#### REFERENCE

Gaillard,Y.; Pépin,G. Use of high-performance liquid chromatography with photodiode-array UV detection for the creation of a 600-compound library. Application to forensic toxicology, *J.Chromatogr.A*, **1997**, 763, 149–163.

---

#### SAMPLE

**Matrix:** solutions

**Sample preparation:** Mix an excess of griseofulvin with 8 mL water or with 8 mL 6-7 mM sodium dodecyl sulfate. Shake in a 25° water bath for 48 h, filter through a 0.45 µm filter. Discard the first a few mL, inject a 150 µL aliquot of the rest.

---

#### HPLC VARIABLES

**Column:** 140 × 4.6 5µm cyanopropyl methyl silane bonded silica (Supelco Inc., PA)

**Mobile phase:** MeOH:water 50:50

**Flow rate:** 1

**Injection volume:** 150

**Detector:** UV 295

---

#### REFERENCE

Rao,V.M.; Lin,M.; Larive,C.K.; Southard,M.Z. A mechanistic study of griseofulvin dissolution into surfactant solutions under laminar flow conditions, *J.Pharm.Sci.*, **1997**, 86, 1132–1137.

---

#### SAMPLE

**Matrix:** solutions

**Sample preparation:** Prepare a solution in mobile phase, inject a 50 µL aliquot.

---

#### HPLC VARIABLES

**Column:** 100 × 4.6 5 µm Spherisorb 5 ODS

**Mobile phase:** MeCN:10 mM phosphoric acid 34:66, pH 2.82

**Column temperature:** 40

**Flow rate:** 1

**Injection volume:** 50

**Detector:** UV 248

---

#### CHROMATOGRAM

**Retention time:** 12.13

**Internal standard:** griseofulvin

---

#### OTHER SUBSTANCES

**Simultaneous:** methoxsalen

---

#### KEY WORDS

SPE; griseofulvin is IS

---

**REFERENCE**

Kucová,D.; Maryšková,D.; Davidková,P.; Gasparic,J. High-performance liquid chromatographic determination of methoxsalen in plasma after liquid-solid extraction, *J.Chromatogr.*, **1993**, 614, 340–344.

---

**SAMPLE**

**Matrix:** solutions

**Sample preparation:** Prepare a solution in MeOH, inject an aliquot.

---

**HPLC VARIABLES**

**Column:** 250 × 4.6 10 µm RP 18

**Mobile phase:** MeOH:water 60:40

**Detector:** UV 245 and 315

---

**CHROMATOGRAM**

**Limit of quantitation:** 500 ng/mL

---


**REFERENCE**

De Smidt,J.H.; Grit,M.; Crommelin,D.J.A. Dissolution kinetics of griseofulvin in mixed micellar solutions, *J.Pharm.Sci.*, **1994**, 83, 1209–1212.

---

---

# Guaiacol



**Molecular formula:** C<sub>7</sub>H<sub>8</sub>O<sub>2</sub>

**Molecular weight:** 124.14

**CAS Registry No.:** 90-05-1

**Merck Index:** 4575

---

**SAMPLE**

**Matrix:** blood, urine

**Sample preparation:** Add 1 mL whole blood or urine to Toxi-Tube A (Toxi-Lab, Irvine CA), add 3 mL water, mix by gentle inversion for 5 min, centrifuge at 1500 g for 5 min. Remove the organic layer and evaporate it to dryness under a stream of nitrogen at 40°, reconstitute the residue with 50 µL MeCN:water 50:50, vortex for 10 s, centrifuge at 7500 g for 2 min, inject a 10 (urine) or 30 (blood) µL aliquot. (The detector wavelength shown is the wavelength of maximum absorbance. This will not necessarily be the optimal wavelength for the separation. Multiple wavelengths from 200–350 nm can be scanned using a diode-array detector. Otherwise, 220 nm may be a reasonable choice for initial work. Matrix may interfere.)

---

**HPLC VARIABLES**

**Guard column:** 20 mm long Symmetry C18

**Column:** 250 × 4.6 5 µm Symmetry C8 (Waters)

**Mobile phase:** Gradient. A was 50 mM pH 3.8 sodium phosphate buffer. B was MeCN. A:B 85:15 for 6.5 min, 65:35 for 18.5 min, 20:80 for 3 min (step gradient), re-equilibrate at initial conditions for 7 min.

**Column temperature:** 30

**Flow rate:** 1 for 6.5 min, to 1.5 over 18.5 min, maintain at 1.5 for 3 min (re-equilibrate at 1.5 mL/min)

**Injection volume:** 10–30

**Detector:** UV 200.5

---

**CHROMATOGRAM**

**Retention time:** 13.787

---

**KEY WORDS**

whole blood

---

**REFERENCE**

Gaillard, Y.; Pépin, G. Use of high-performance liquid chromatography with photodiode-array UV detection for the creation of a 600-compound library. Application to forensic toxicology, *J. Chromatogr. A*, **1997**, 763, 149–163.

---

**SAMPLE**

**Matrix:** solutions

---

**HPLC VARIABLES**

**Column:** 250 × 4.6 Zorbax RX

**Mobile phase:** Gradient. A was 10 mL concentrated orthophosphoric acid and 7 mL triethylamine in 1 L water. B was 10 mL concentrated orthophosphoric acid and 7 mL triethylamine in 200 mL water, make up to 1 L with MeCN. A:B from 100:0 to 0:100 over 30 min, maintain at 0:100 for 5 min.

**Column temperature:** 30

**Flow rate:** 2

**Detector:** UV 210

---


**OTHER SUBSTANCES**

**Also analyzed:** acepromazine, acetaminophen, acetophenazine, albuterol, aminophylline, amitriptyline, amobarbital, amoxapine, amphetamine, amylocaine, antipyrine, aprobarbital, aspirin, atenolol, atropine, avermectin, barbital, benzocaine, benzoic acid, benzotriptine, benzphetamine, berberine, bibucaine, bromazepam, brompheniramine, buprenorphine, buspirone, butabarbital, butacaine, butethal, caffeine, carbamazepine, carbromal, chloramphenicol, chlor-diazepoxide, chloroquine, chlorothiazide, chloroxylenol, chlorphenesin, chlorpheniramine, chlorpromazine, chlorpropamide, chlortetracycline, cimetidine, cinchonidine, cinchonine, clenbuterol, clonazepam, clonixin, clorazepate, cocaine, codeine, colchicine, cortisone, coumarin, cyclazocine, cyclobenzaprine, cyclothiazide, cyheptamide, cymarin, danazol, danthron, dapsone, debrisoquine, desipramine, dexamethasone, dextromethorphan, dextropropoxyphene, diamorphine, diazepam, diclofenac, diethylpropion, diethylstilbestrol, diflunisal, digitoxin, digoxin, diltiazem, diphenhydramine, diphenoxylate, diprenorphine, dipyrone, disulfiram, dopamine, doxapram, doxepin, dronabinol, ephedrine, epinephrine, epinine, estradiol, estriol, estrone, ethacrynic acid, ethosuximide, etonitazene, etorphine, eugenol, famotidine, fenbendazole, fencamfamine, fenpropofen, fenproporex, fentanyl, flubendazole, flufenamic acid, flunitrazepam, 5-fluorouracil, fluoxymesterone, fluphenazine, furosemide, gentisic acid, gitoxigenin, glipizide, glunixin, glutethimide, halazepam, haloperidol, hydrochlorothiazide, hydrocodone, hydrocortisone, hydromorphone, hydroxyquinoline, ibogaine, ibuprofen, iminostilbene, imipramine, indomethacin, isocarbostyryl, isocarboxazid, isoniazid, isoproterenol, isoxsuprine, ivermectin, ketamine, ketoprofen, kynurenic acid, levorphanol, lidocaine, lorazepam, lormetazepam, loxapine, mazindol, mebendazole, meclizine, meclofenamic acid, medazepam, mefenamic acid, megestrol, mepacrine, meperidine, mephentermine, mephénytoin, mephesin, mephobarbital, mepivacaine, mescaline, mesoridazine, methadone, methamphetamine, methapyrilene, methaqualone, methazolamide, methocarbamol, methoxamine, methsuximide, methyl salicylate, methyl dopa, methyl dopamine, methylphenidate, methylprednisolone, methyltestosterone, methylpyrrolone, metoprolol, mibolerone, morphine, nadolol, nalorphine, naloxone, naltrexone, naphazoline, naproxen, nefopam, niacinamide, nicotine, niacin, nifedipine, niflumic acid, nitrazepam, nor-epinephrine, nortriptyline, noscapine, nylidrin, oxazepam, oxycodone, oxymorphone, oxyphenbutazone, oxytetracycline, papaverine, pargyline, pemoline, pentazocine, pentobarbital, persantine, phenacetin, phenazocine, phenazopyridine, phenacyclidine, phendimetrazine, phenelzine, pheniramine, phenobarbital, phenothiazine, phensuximide, phentermine, phenylbutazone, phenylephrine, phenylpropanolamine, piperocaine, prazepam, prednisolone, primidone, probenecid, progesterone, propiomazine, propranolol, propylparaben, pseudoephedrine, puromycin, pyrilamine, pyrithyldione, quazepam, quinaldic acid, quinidine, quinine, ranitidine, recinnamine, reserpine, resorcinol, saccharin, albuterol, salicylamide, salicylic acid, scopalamine, scopolin, secobarbital, strychnine, sulfacetamide, sufadiazine, sulfadimethoxine, sulfathiazole, sulfamerazine, sulfamethazine, sulfamethoxazole, sulfanilamide, sulfapyridine, sulfasoxazole, sulindac, tamoxifen, temazepam, testosterone, tetracaine, tetracycline, tetramisole, thebaine, theobromine, theophylline, thiabendazole, thiamine, thiamylal, thiobarbituric acid, thioridazine, thiosalicylic acid, thiothixene, thymol, tolazamide, tolazoline, tobutamide, tolmetin, tranlycypromine, triamcinolone, tribenzylamine, trichloromethiazide, trifluoperazine, trihexyphenidyl, trimethoprim, tripelennamine, triprolidine, tropacocaine, tyramine, verapamil, vincamine, warfarin, yohimbine, zoxazolamine

**REFERENCE**

Hill,D.W.; Kind,A.J. Reversed-phase solvent gradient HPLC retention indexes of drugs, *J.Anal.Toxicol.*, **1994**, *18*, 233-242.

# Guaifenesin



**Molecular formula:** C<sub>10</sub>H<sub>14</sub>O<sub>4</sub>

**Molecular weight:** 198.22

**CAS Registry No.:** 93-14-1

**Merck Index:** 4582

**Lednicer No.:** 1 118

**SAMPLE**

**Matrix:** blood

**Sample preparation:** 500 µL Plasma + 100 µL 2.5 mg/mL O-desmethylnaproxen in MeOH + 400 µL acetone, homogenize for 10 min, centrifuge at 1000 g for 15 min. Remove supernatant and evaporate it to dryness under a stream of air at 35°. Take up residue in 500 µL mobile phase, inject 10 µL aliquot.

**HPLC VARIABLES**

**Column:** 150 × 4.6 5 µm LiChrosorb RP-18

**Mobile phase:** MeOH:10 mM pH 6.5 citrate buffer 10:90

**Column temperature:** 35

**Flow rate:** 2

**Injection volume:** 10

**Detector:** F ex 230 em 306

**CHROMATOGRAM**

**Retention time:** 37

**Internal standard:** O-desmethylnaproxen (26)

**OTHER SUBSTANCES**

**Simultaneous:** metabolites

**KEY WORDS**

plasma; horse

**REFERENCE**

Ketelaars,H.C.; Peters,J.G.; Anzion,R.B.; Van Ginneken,C.A. Isolation, partial identification and quantitative determination of four guaifenesin glucuronides in plasma and urine of the horse by high-performance liquid chromatography, *J.Chromatogr.*, **1984**, *288*, 423-429.

**SAMPLE**

**Matrix:** blood, urine

**Sample preparation:** Add 1 mL whole blood or urine to Toxi-Tube A (Toxi-Lab, Irvine CA), add 3 mL water, mix by gentle inversion for 5 min, centrifuge at 1500 g for 5 min. Remove the organic layer and evaporate it to dryness under a stream of nitrogen at 40°, reconstitute the residue with 50 µL MeCN:water 50:50, vortex for 10 s, centrifuge at 7500 g for 2 min, inject a 10 (urine) or 30 (blood) µL aliquot. (The detector wavelength shown is the wavelength of maximum absorbance. This will not necessarily be the optimal wavelength for the separation. Multiple wavelengths from 200-350 nm can be scanned using a diode-array detector. Otherwise, 220 nm may be a reasonable choice for initial work. Matrix may interfere.)

**HPLC VARIABLES**

**Guard column:** 20 mm long Symmetry C18

**Column:** 250 × 4.6 5 µm Symmetry C8 (Waters)

**Mobile phase:** Gradient. A was 50 mM pH 3.8 sodium phosphate buffer. B was MeCN. A:B 85:15 for 6.5 min, 65:35 for 18.5 min, 20:80 for 3 min (step gradient), re-equilibrate at initial conditions for 7 min.

**Column temperature:** 30

**Flow rate:** 1 for 6.5 min, to 1.5 over 18.5 min, maintain at 1.5 for 3 min (re-equilibrate at 1.5 mL/min)

**Injection volume:** 10-30

**Detector:** UV 200.5

---

#### CHROMATOGRAM

**Retention time:** 11.435

---

#### KEY WORDS

whole blood

---

#### REFERENCE

Gaillard,Y.; Pépin,G. Use of high-performance liquid chromatography with photodiode-array UV detection for the creation of a 600-compound library. Application to forensic toxicology, *J.Chromatogr.A*, **1997**, 763, 149-163.

---

#### SAMPLE

**Matrix:** bulk

**Sample preparation:** Dissolve in mobile phase, inject a 20 µL aliquot.

---

#### HPLC VARIABLES

**Column:** 250 × 4.6 10 µm Chiralcel OD

**Mobile phase:** EtOH:heptane 20:80

**Flow rate:** 1

**Injection volume:** 20

**Detector:** UV 365

---

#### CHROMATOGRAM

**Retention time:** k' 0.57 ((R)-(-)), k'1.72 ((S)-(+))

---

#### KEY WORDS

chiral


---

#### REFERENCE

Francotte,E.R.; Richert,P. Applications of simulated moving-bed chromatography to the separation of the enantiomers of chiral drugs, *J.Chromatogr.A*, **1997**, 769, 101-107.

---

# Guanabenz



**Molecular formula:** C<sub>8</sub>H<sub>8</sub>Cl<sub>2</sub>N<sub>4</sub>

**Molecular weight:** 231.08

**CAS Registry No.:** 5051-62-7, 23256-50-0 (acetate)

**Merck Index:** 4585

**Lednicer No.:** 2 123

---

#### SAMPLE

**Matrix:** formulations

**Sample preparation:** Finely powder tablets, weigh out amount equivalent to 30 mg guanabenz acetate, add 190 mL MeCN, sonicate for a few minutes, make up to 200 mL with MeCN, filter. Remove a 14-59 mL aliquot and add it to 9 mL 1 mg/mL carbamazepine in MeCN, make up to 100 mL with MeCN, inject a 20 µL aliquot.

**HPLC VARIABLES****Column:** 250 × 4.6 10 μm octadecylsilane (Perkin-Elmer)**Mobile phase:** MeCN:buffer 35:65 (Buffer was 4 mM KH<sub>2</sub>PO<sub>4</sub> adjusted to pH 3.25 with phosphoric acid.)**Flow rate:** 2.5**Injection volume:** 20**Detector:** UV 265

---

**CHROMATOGRAM****Retention time:** 2**Internal standard:** carbamazepine (3)

---

**OTHER SUBSTANCES****Simultaneous:** mefruside, impurities

---

**KEY WORDS**tablets

---

**REFERENCE**Vio,L.; Mamolo,M.G.; Furlan,G. Quantitative high pressure liquid chromatographic determination of guanabenz and mephroside in pharmaceutical formulations, *Farmaco.[Prat.]*, **1988**, *43*, 27–36.

---

**SAMPLE****Matrix:** formulations**Sample preparation:** Dilute a 500 μL aliquot of syrup with water to give a clonidine concentration of 5 μg/mL, filter (0.22 μm), inject a 15 μL aliquot.

---

**HPLC VARIABLES****Column:** 250 × 4.6 5 μm Zorbax TMS trimethylsilyl**Mobile phase:** MeOH:buffer 65:35 (Buffer was 2.2 mM KH<sub>2</sub>PO<sub>4</sub> and 16 mM Na<sub>2</sub>HPO<sub>4</sub>, pH 7.9.)**Flow rate:** 1**Injection volume:** 15**Detector:** UV 254

---

**CHROMATOGRAM****Retention time:** 7**Internal standard:** guanabenz

---

**OTHER SUBSTANCES****Simultaneous:** clonidine


---

**KEY WORDS**syrup; guanabenz is IS

---

**REFERENCE**Levinson,M.L.; Johnson,C.E. Stability of an extemporaneously compounded clonidine hydrochloride oral liquid, *Am.J.Hosp.Pharm.*, **1992**, *49*, 122–125.

# Guanethidine



**Molecular formula:**  $C_{10}H_{22}N_4$

**Molecular weight:** 198.31

**CAS Registry No.:** 55-65-2, 645-43-2 (monosulfate), 60-02-6 (sulfate)

**Merck Index:** 4589

**Lednicer No.:** 1 282

## SAMPLE

**Matrix:** blood

**Sample preparation:** Inject 200  $\mu$ L serum onto column A and elute to waste with mobile phase A, after 2 min elute the contents of column A onto column B with mobile phase B, after another 3 min remove column A from the circuit, elute column B with mobile phase B, monitor the effluent from column B. Flush column A with mobile phase C for 10 min, re-equilibrate with mobile phase A for 7 min.

## HPLC VARIABLES

**Column:** A  $35 \times 4.6$  10  $\mu$ m TSK precolumn BSA-ODS (Tosoh); B  $150 \times 4.6$  5  $\mu$ m TSKgel ODS-80TM (Tosoh)

**Mobile phase:** A 50 mM  $NaH_2PO_4$  adjusted to pH 3.0 with 50 mM phosphoric acid; B MeCN: buffer 30:70, containing 7 g/L sodium 1-octanesulfonate (Buffer was 50 mM  $NaH_2PO_4$  adjusted to pH 3.0 with 50 mM phosphoric acid.); C MeCN:water 50:50.

**Flow rate:** 1

**Injection volume:** 200

**Detector:** F ex 39 em 500 following post-column reaction. The effluent from column B mixed with 1 M NaOH pumped at 0.3 mL/min and with 6 g/L ninhydrin in water pumped at 0.3 mL/min and the mixture flowed through a 10 m  $\times$  0.5 mm ID PTFE coil at 56° to the detector.

## CHROMATOGRAM

**Retention time:** 16

**Limit of detection:** 1 ng/mL

**Limit of quantitation:** 3.1 ng/mL

## KEY WORDS

serum; post-column reaction; column-switching; rat; human; pharmacokinetics

## REFERENCE

Inamoto,Y.; Inamoto,S.; Hanai,T.; Takahashi,Y.; Kadowaki,K.; Kinoshita,T. Development of automated highly sensitive analytical system for guanethidine sulfate in serum, *J.Liq.Chromatogr.Rel.Technol.*, **1997**, 20, 2099–2108.

## SAMPLE

**Matrix:** formulations

**Sample preparation:** Grind tablets, add 3-20 mL MeCN:water 15:85, sonicate for 10 min, filter, make up to 100 mL with MeCN:water 15:85. Remove a 500  $\mu$ L aliquot and add it to 300  $\mu$ L 250  $\mu$ g/mL procaine hydrochloride in water, make up to 10 mL with mobile phase, inject a 50  $\mu$ L aliquot.

## HPLC VARIABLES

**Column:** 250  $\times$  4.6 5  $\mu$ m ASI chromosphere 3869 octadecylsilane (Analytical Sciences, Inc.)

**Mobile phase:** MeCN:50 mM  $NaH_2PO_4$  30:70 containing sodium pentanesulfonate, pH adjusted to 2.5 with concentrated phosphoric acid

**Flow rate:** 1

**Injection volume:** 50

**Detector:** E, Metrohm model E-611, Bioanalytical Systems Kel F cell, glassy carbon electrode + 1300 mV, auxiliary platinum electrode, Ag/AgCl reference electrode

## CHROMATOGRAM

**Retention time:** 3.5



**Internal standard:** procaine hydrochloride (5.7)

**Limit of quantitation:** 500 ng/mL

---

**OTHER SUBSTANCES**

**Simultaneous:** hydrochlorothiazide

---

**KEY WORDS**

tablets; not stability-indicating

---

**REFERENCE**

Stewart,J.T.; Clark,S.S. Liquid chromatographic determination of guanethidine salts and hydrochlorothiazide using electrochemical detection and ion-pair techniques, *J.Pharm.Sci.*, **1986**, 75, 413–415.

---

**SAMPLE**

**Matrix:** solutions

---

**HPLC VARIABLES**

**Column:**  $\mu$ Bondapak CN

**Mobile phase:** MeCN:0.1% pH 7.36 ammonium acetate 50:50

**Flow rate:** 2

**Detector:** UV 206

---

**CHROMATOGRAM**

**Retention time:** 2

**Limit of detection:** 20 ng

---

**KEY WORDS**

rabbit; buffer


---

**REFERENCE**

Tang-Liu,D.D.-S.; Richman,J.B.; Weinkam,R.J.; Takruri,H. Effects of four penetration enhancers on corneal permeability of drugs in vitro, *J.Pharm.Sci.*, **1994**, 83, 85–90.

---

# Guanfacine



**Molecular formula:** C<sub>9</sub>H<sub>9</sub>Cl<sub>2</sub>N<sub>3</sub>O

**Molecular weight:** 246.10

**CAS Registry No.:** 29110-47-2, 29110-48-3 (HCl)

**Merck Index:** 4590

**Lednicer No.:** 3 40

---

**SAMPLE**

**Matrix:** blood, urine

**Sample preparation:** Add 1 mL whole blood or urine to Toxi-Tube A (Toxi-Lab, Irvine CA), add 3 mL water, mix by gentle inversion for 5 min, centrifuge at 1500 g for 5 min. Remove the organic layer and evaporate it to dryness under a stream of nitrogen at 40°, reconstitute the residue with 50  $\mu$ L MeCN:water 50:50, vortex for 10 s, centrifuge at 7500 g for 2 min, inject a 10 (urine) or 30 (blood)  $\mu$ L aliquot. (The detector wavelength shown is the wavelength of maximum absorbance. This will not necessarily be the optimal wavelength for the separation. Multiple wavelengths from 200-350 nm can be scanned using a diode-array detector. Otherwise, 220 nm may be a reasonable choice for initial work. Matrix may interfere.)

---

**HPLC VARIABLES**

**Guard column:** 20 mm long Symmetry C18

**Column:** 250  $\times$  4.6 5  $\mu$ m Symmetry C8 (Waters)

**Mobile phase:** Gradient. A was 50 mM pH 3.8 sodium phosphate buffer. B was MeCN. A:B 85:15 for 6.5 min, 65:35 for 18.5 min, 20:80 for 3 min (step gradient), re-equilibrate at initial conditions for 7 min.

**Column temperature:** 30

**Flow rate:** 1 for 6.5 min, to 1.5 over 18.5 min, maintain at 1.5 for 3 min (re-equilibrate at 1.5 mL/min)

**Injection volume:** 10-30

**Detector:** UV 200.5

---

## CHROMATOGRAM

**Retention time:** 11.387

---

## KEY WORDS

whole blood


---

## REFERENCE

Gaillard, Y.; Pépin, G. Use of high-performance liquid chromatography with photodiode-array UV detection for the creation of a 600-compound library. Application to forensic toxicology, *J. Chromatogr. A*, **1997**, *763*, 149-163.

---

# Gusperimus



**Molecular formula:** C<sub>17</sub>H<sub>37</sub>N<sub>7</sub>O<sub>3</sub>

**Molecular weight:** 387.53

**CAS Registry No.:** 104317-84-2, 84937-45-1 ((-)-form tri HCl), 85468-01-5 (tri HCl)

**Merck Index:** 4610

---

## SAMPLE

**Matrix:** blood

**Sample preparation:** 1 mL Plasma + 10 µg IS, mix well, make up to 10 mL with water, add to a 50 × 6 column of CM-Sephadex C-25, wash with 10 mL 300 mM NaCl, elute with 10 mL 400 mM NaCl, add the eluate to a Sep-Pak C18 SPE cartridge, wash with 5 mL water, elute with 10 mL MeOH. Evaporate the eluate to dryness under reduced pressure, reconstitute the residue in 200 µL mobile phase, vortex, inject a 50 µL aliquot.

---

## HPLC VARIABLES

**Guard column:** Guard Pak C18 (Waters)

**Column:** 150 × 4.6 Cosmosil 5C18-P (Nacalai Tesque)

**Mobile phase:** MeCN:buffer 9:91 (Buffer was 10 mM pH 3 phosphate buffer containing 5 mM sodium pentanesulfonate.)

**Flow rate:** 1

**Injection volume:** 50

**Detector:** UV 205

---

## CHROMATOGRAM

**Retention time:** 8.6

**Internal standard:** 1-amino-20-guanidino-11-hydroxy-4,9,12-triazaeicosane-10,13-dione (Heat 33.7 mmole 8-guanidinooctanamide, 30.7 mmole glyoxylspermidine hydrochloride, 33.7 mmole glutaric acid, and 2 g water at 60° for 8 h, dilute with water, chromatograph on CM-Sephadex C-25(Na<sup>+</sup>) using gradient elution with water and 1 M NaCl. Evaporate the eluate fraction containing the product to dryness, extract the residue with MeOH, chromatograph the extract on Sephadex LH-20 with MeOH, evaporate the eluate to dryness to get the compound.) (18.6)

**Limit of quantitation:** 50 ng/mL

---

## KEY WORDS

dog; plasma; SPE; pharmacokinetics

---

**REFERENCE**

Nakanuma,R.; Watanabe,K.; Yamashita,K.; Mizuguchi,S.; Hashimoto,Y.; Nakamura,T.; Umezawa,H. High-performance liquid chromatographic determination of deoxyspergualin in dog plasma with ultraviolet detection, *J.Chromatogr.*, **1990**, 527, 208-213.

---

**SAMPLE**

**Matrix:** blood

**Sample preparation:** Filter (Amicon MPS-1 with 14 mm YM20 membrane) 1 mL plasma while centrifuging at 800 g for 1 h. Remove a 400  $\mu$ L aliquot of the ultrafiltrate and add it to 50  $\mu$ L 500 mM pH 6.8 phosphate buffer, add 50  $\mu$ L 10 mM NaCN in water, add 100  $\mu$ L 2 mM naphthalene-2,3-dicarboxaldehyde in MeCN, let stand at room temperature for 15 min, add 50  $\mu$ L 500 mM pH 3.0 sodium acetate buffer, inject an aliquot.

---

**HPLC VARIABLES**

**Column:** 150  $\times$  4.6 5  $\mu$ m ODS Hypersil

**Mobile phase:** MeCN:100 mM  $\text{KH}_2\text{PO}_4$ :phosphoric acid 52:48:0.8 containing 18 mM sodium dodecyl sulfate

**Column temperature:** 40  $\pm$  0.1

**Flow rate:** 2

**Injection volume:** 50

**Detector:** F ex 420 em 490

---

**CHROMATOGRAM**

**Retention time:** 14

**Limit of quantitation:** 5 ng/mL

---

**KEY WORDS**

derivatization; plasma; ultrafiltrate

---

**REFERENCE**

Sprancmanis,L.A.; Riley,C.M.; Stobaugh,J.F. Determination of the anticancer drug, 15-deoxyspergualin, in plasma ultrafiltrate by liquid chromatography and precolumn derivatization with naphthalene-2,3-dicarboxaldehyde/cyanide, *J.Pharm.Biomed.Anal.*, **1990**, 8, 165-175.

---

**SAMPLE**

**Matrix:** blood, urine

**Sample preparation:** Plasma. 750  $\mu$ L Plasma + 30  $\mu$ L 70% perchloric acid, vortex, centrifuge at 15600 g for 5 min, filter (0.22  $\mu$ m) the supernatant, inject a 10-200  $\mu$ L aliquot of the filtrate. Urine. Dilute urine 10 to 25-fold with water, centrifuge, filter (0.22  $\mu$ m) the supernatant, inject a 10-200  $\mu$ L aliquot of the filtrate.

---

**HPLC VARIABLES**

**Guard column:** 15  $\times$  3.2 7  $\mu$ m Newguard RP 18

**Column:** two 100  $\times$  4.6 5  $\mu$ m RP 18 columns in series (Brownlee)

**Mobile phase:** Gradient. A was MeCN:100 mM pH 2.55  $\text{NaH}_2\text{PO}_4$  containing 8 mM octanesulfonic acid and 0.1 mM EDTA 2:98. B was MeCN:200 mM pH 3.1  $\text{NaH}_2\text{PO}_4$  containing 8 mM octanesulfonic acid 30:70. A:B from 55:45 to 25:75 over 20 min.

**Flow rate:** 1

**Injection volume:** 10-200

**Detector:** F ex 340 em 440 following post-column reaction. The column effluent mixed with the reagent pumped at 0.7 mL/min and flowed through a 2 m long reaction coil at 41° to the detector. The reagent was 500 mM pH 8.8 potassium borate buffer containing 0.8 g/L o-phthalaldehyde, 1% MeOH, and 0.06% 2-mercaptoethanol.

---

**CHROMATOGRAM**

**Retention time:** 22

**Limit of quantitation:** 100 nM

---

**OTHER SUBSTANCES**

**Extracted:** metabolites

**KEY WORDS**

use plasticware; plasma; post-column reaction; pharmacokinetics

**REFERENCE**

Muindi,J.F.; Lee,S.-J.; Baltzer,L.; Jakubowski,A.; Scher,H.I.; Sprancmanis,L.A.; Riley,C.M.; Vander Velde,D.; Young,C.W. Clinical pharmacology of deoxyspergualin in patients with advanced cancer, *Cancer Res.*, **1991**, *51*, 3096-3101.


# Halazepam

**Molecular formula:** C<sub>17</sub>H<sub>12</sub>ClF<sub>3</sub>N<sub>2</sub>O

**Molecular weight:** 352.74

**CAS Registry No.:** 23092-17-3

**Merck Index:** 4619

**SAMPLE**

**Matrix:** blood

**Sample preparation:** Condition a Bond-Elut C8 SPE cartridge with 2 mL MeOH and 2 mL water, do not allow to dry. Add 100  $\mu$ L 5 ng/mL diazepam in 1 M pH 10.5 glycine buffer then 1 mL plasma to the SPE cartridge, wash with 2 mL water, wash with 50  $\mu$ L MeOH, elute with three 200  $\mu$ L aliquots of MeOH. Combine the eluates and evaporate them to dryness under a stream of nitrogen at 37°, reconstitute the residue in 100  $\mu$ L mobile phase, inject a 50-80  $\mu$ L aliquot.

**HPLC VARIABLES**

**Column:** 100  $\times$  4.6 3  $\mu$ m Adsorbosphere C8

**Mobile phase:** MeOH:20 mM pH 4.0 phosphate buffer 60:40

**Flow rate:** 1

**Injection volume:** 50-80

**Detector:** UV 240

**CHROMATOGRAM**

**Retention time:** 9.31

**Internal standard:** diazepam (7.76)

**Limit of quantitation:** 1 ng/mL

**OTHER SUBSTANCES**

**Extracted:** nordiazepam

**Simultaneous:** alprazolam, chlordiazepoxide, clonazepam, desmethyldiazepam, 3-hydroxyhalazepam, lorazepam, methylclonazepam, oxazepam, prazepam, quazepam, temazepam, triazolam

**KEY WORDS**

SPE; plasma; pharmacokinetics

**REFERENCE**

Gupta,S.K.; Ellinwood,E.H. Liquid chromatographic assay and pharmacokinetics of halazepam and its metabolite in humans, *J.Pharm.Sci.*, **1990**, *79*, 822-825.

**SAMPLE**

**Matrix:** microsomal incubations

**Sample preparation:** 2.5 mL Microsomal incubation + 2.5 mL acetone, add 30  $\mu$ L diazepam in MeOH, add 2.5 mL chloroform, centrifuge. Remove the organic layer and evaporate it to dryness under reduced pressure at 40°, reconstitute the residue in 100  $\mu$ L mobile phase, inject an aliquot.

**HPLC VARIABLES**

**Column:** 250  $\times$  6.2 7  $\mu$ m Zorbax silica